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ABSTRACT OF DISSERTATION 
 
THE ROLE OF NRF2 SIGNALLING IN CELL PROLIFERATION AND 
TUMORIGENESIS OF CHROMIUM TRANSFORMED HUMAN BRONCHIAL 
EPITHELIAL CELLS 
Hexavalent Chromium (Cr(VI) induces malignant cell transformation in 
normal bronchial epithelial (BEAS-2B) cells. Cr(VI)-transformed cells exhibit 
increased level of antioxidants, are resistant to apoptosis, and are tumorigenic. 
RNAseq analysis in Cr(VI)-transformed cells showed that expression of 
transcripts associated with mitochondrial oxidative phosphorylation is reduced, 
and the expression of transcripts associated with pentose phosphate pathway, 
glycolysis, and glutaminolysis are increased. Sirtuin-3 (SIRT3) regulates 
mitochondrial adaptive response to stress, such as metabolic reprogramming 
and antioxidant defense mechanisms. SIRT3 was upregulated and it positively 
regulated mitochondrial oxidative phosphorylation in Cr(VI)-transformed cells. 
Our results suggests that SIRT3 plays an important role in mitophagy deficiency 
of Cr(VI)-transformed cells. Furthermore, SIRT3 knockdown suppressed cell 
proliferation and tumorigenesis of Cr(VI)-transformed cells. Nrf2 is a transcription 
factor that regulates oxidative stress response. This study investigated the role of 
Nrf2 in regulating metabolic reprogramming in Cr(VI)-transformed cells. We 
observed that in Cr(VI)-transformed cells p-AMPKthr172 was increased, when 
compared to normal BEAS-2B cells. Additionally, Nrf2 knockdown reduced p-
AMPKthr172. Our results suggest that Nrf2 regulated glycolytic shift via AMPK 
regulation of PFK1/PFK2 pathway. Furthermore, our results showed that Nrf2 
constitutive activation in Cr(VI-transformed cells increased cell proliferation and 
tumorigenesis. Overall this dissertation demonstrated that Cr(VI)-transformed 
cells undergo metabolic reprogramming. We demonstrated that Nrf2 constitutive 
activation plays decisive role on metabolic reprogramming induction, and SIRT3 
activation contributing to increased cancer cell proliferation and tumorigenesis. 
 
KEYWORDS: Metabolic Reprogramming, Hexavalent Chromium, SIRT3, Nrf2, 
AMPK.  
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CHAPTER 1. OXIDATIVE STRESS AND METABOLIC REPROGRAMMING IN CR(VI) 
CARCINOGENESIS 
1.1 Abstract 
Cr(VI)-containing compounds are well-established lung carcinogens. 
Chronic exposure of human bronchial epithelial cells (BEAS-2B) to Cr(VI) is able 
to induce malignant cell transformation, the first stage of metal carcinogenesis. 
These Cr(VI)-transformed cells exhibit increased levels of antioxidants, reduced 
capacity of generating reactive oxygen species (ROS), and increased apoptosis 
resistance, which together promote tumorigenesis of Cr(VI)-transformed cells, 
the second stage of Cr(VI)-carcinogenesis. The mechanism of Cr(VI)-induced 
carcinogenesis is still under investigation. Recent studies indicated that 
increased ROS generation causes malignant cell transformation, the first stage of 
Cr(VI) carcinogenesis. Reduced ROS generation causes development of 
apoptosis resistance of Cr(VI)-transformed cells, the second stage of Cr(VI)-
carcinogenesis. Malignant transformed cells adapt metabolism to support tumor 
initiation and progression. Altered metabolic activities directly participate in the 
process of cell transformation or support a large requirement for nucleotides, 
amino acids, and lipids for tumor growth. In Cr(VI)-transformed cells, 
mitochondrial oxidative phosphorylation is defective, and pentose phosphate 
pathway, glycolysis, and glutaminolysis are upregulated. These metabolic 
reprogramming supports rapid cell proliferation and contributes to tumorigenesis 
of Cr(VI)-transformed cells. This chapter summarizes the current progress in the 
studies of metabolic reprogramming and Cr(VI) carcinogenesis with emphasis on 
the metabolic enzymes and oxidative stress related major oncogenic pathways. 
1.2 Introduction 
When normal cells are converted to malignantly transformed cells and 
progress to cancer, their metabolism is altered. In contrast to the normal 
2 
 
differentiated cells which rely mainly on mitochondrial oxidative phosphorylation 
(OXPHOS) for generation of needed energy, cancer cells depend on anaerobic 
glycolysis, a phenomenon called “the Warburg effect” for energy. This altered 
cellular metabolism, also called metabolic reprogramming, is recognized as one 
of the cancer phenotypes. Accumulative evidence reveals that various oncogenic 
pathways are involved in the metabolic regulation. Expression of glucose 
transporters and glycolytic enzymes are increased in numerous cancers and may 
contribute to tumor progression (Majumder et al. 2004; Shackelford et al. 2009). 
It has been reported that oncogenes and tumor suppressor genes, such as 
hypoxia inducible factor 1 (HIF-1) (Stohs et al. 2000), c-Myc (Wang et al. 2011; 
Yao et al. 2008; Ye et al. 1995), p53 (Barchowsky et al. 1999; Liu et al. 2001), 
and PI3K/Akt (Harris and Shi 2003), directly promote metabolism of glucose and 
glutamine.  
Chromate (Cr(VI)) compounds, widely used in industry, have been shown 
to be toxic and carcinogenic on humans (Langard 1990; 1993; Machle and 
Gregorius 1948; Wilbur et al. 2012). Cr(VI) is structurally similar to sulfate and 
phosphate anions; therefore, it readily enters into the cells via non-specific anion 
transporters (Zhitkovich 2011). Once inside the cells, Cr(VI) undergoes a series 
of metabolic reductions and forms intermediate Cr species, including Cr(V) and 
Cr(IV), and is finally reduced to Cr(III) (Zhitkovich 2005; 2011). In the Cr(VI) 
reduction process, reactive oxygen species (ROS) are produced, resulting in 
oxidative DNA damage. The intermediates Cr(V) and Cr(IV) and the final product 
Cr(III) are very reactive, causing Cr-DNA adducts and genomic alterations. 
Epidemiological studies have shown that occupational exposure to Cr(VI) is 
associated with a high rate of lung cancer in workers employed in these 
industries (Langard 1990; 1993; Machle and Gregorius 1948; Wilbur et al. 2012). 
Environmental Cr(VI) exposure is also a public health concern and is associated 
with long-term carcinogenic effects of the lung (Langard 1993; Woodruff et al. 
1998). Though the mechanisms of Cr(VI) carcinogenesis have not yet been fully 
understood, is generally believed that ROS are important in inducing malignant 
cell transformation, the first stage of metal carcinogenesis (Shi and Dalal 1989; 
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Wang et al. 2011; Yao et al. 2008; Ye et al. 1995). ROS can be involved in 
various carcinogenic processes (Shi and Dalal 1989). Recent studies from our 
laboratory has shown that once cells are malignantly transformed, the capacity of 
those transformed cells to generate ROS is sharply reduced, leading to the 
development of apoptosis resistant and subsequent tumorigenesis (Zhang et al. 
2015b). Thus, the decreased ROS generation in Cr(VI)-transformed cells is 
oncogenic in promoting tumorigenesis, the second stage of metal 
carcinogenesis. The oncogenic role of ROS in the first stage of Cr(VI) 
carcinogenesis (malignant cell transformation) and anti-oncogenic role in the 
second stage (tumorigenesis) reflects the metabolic reprogramming during the 
change from normal cells to malignantly transformed cells. Although this 
reprogramming may play an important role in the mechanism of metal 
carcinogenesis in general and Cr(VI) carcinogenesis in particular, its underlying 
mechanism remains to be investigated. This chapter provides an outline on 
progress and future perspectives in oxidative stress and metabolic 
reprogramming in Cr(VI) carcinogenesis. 
1.3 Glycolysis  
Glucose homeostasis is controlled by glycolysis/oxidative phosphorylation 
(OXPHOS) and gluconeogenesis pathway. Glycolysis is the enzymatic 
conversion of glucose into lactate, which produces 2 ATP per glucose molecule. 
In the presence of oxygen, normal cells primarily adopt mitochondrial OXPHOS 
to produce 36 ATP per glucose molecule. Cancer cells favor aerobic glycolysis 
over OXPHOS to meet their energy demand, suggesting that cancer cells are 
adapted to survive and proliferate in the absence of mitochondrial ATP 
production. The mitochondria play a major role in supplying energy and 
regulating ROS. Although various mechanisms of carcinogenesis induced by 
Cr(VI) have been demonstrated, it is generally believed that Cr(VI)-induced 
oxidative stress is important in converting normal cells to malignantly transformed 
cells. It has been reported that Cr(VI) suppressed all five mitochondrial 
complexes involved in OXPHOS in a variety of model systems with more potency 
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of complexes I, II, and V than complexes III and IV. Our study showed that in 
Cr(VI)-transformed cells, mitochondrial ATP production was reduced and non-
mitochondrial oxygen consumption was increased, indicating a defect in 
mitochondrial ATP production (Dai et al. 2017). The results from RNA 
sequencing analysis showed in Cr(VI)-transformed cells compared to passage 
matched cells, the levels of various enzymes involved in all five complexes was 
reduced (Table 2), demonstrating that Cr(VI)-transformed cells are defective in 
mitochondrial ATP generation.  
Aerobic glycolysis, maximizing ATP production, does not require an 
increase in mitochondrial capacity (Fan et al. 2013). Cr(VI)-transformed cells 
generated more lactate without significant changes in glucose uptake and ATP 
production, indicating a switch from mitochondrial respiration to glycolysis (Dai et 
al. 2017). The results from Table 1 show that several glycolysis enzymes 
including ADP-specific glucokinase (ADPGK), enolase 1 (ENO1), hexokinase 
(HK2), phosphoglycerate kinase (PGK1), dihydrolipoamide S-acetyltransferase 
(DLAT), pyruvate dehydrogenase E1 (PDHA1), glucose-6-phosphatase 3 
(G6PC3), pyruvate kinase (PKM), aldolase A (ALDOA), phosphofructokinase 
(PFKM) were upregulated in Cr(VI)-transformed cells, indicating that Cr(VI)-
transformed cells utilize glycolysis for energy for survival under defective 
mitochondrial function. It should be noted that many metabolic enzymes are 
regulated through allostery and/or post-translation. For example, pyruvate 
dehydrogenase, a complex with multiple subunits and cofactors, whose activity is 
regulated by phosphorylation/dephosphorylation. Thus characterization of 
metabolic flux together with transcriptomics is a more appropriate way to 
evaluate the metabolic changes upon Cr(VI) exposure. Cancer stem cells (CSCs) 
or cancer-initiating cells, a small subset of malignant cells that exhibit high 
capacity of self-renewal and differentiation, have been reported to utilize aerobic 
glycolysis for biosynthesis and energy requirement (Dong et al. 2013). About 1% 
of Cr(VI)-transformed cells have been identified as CSCs and these CSCs are 
metabolically inactive as evidenced by dramatic reductions of glucose uptake, 
lactate production, and ATP content (Dai et al. 2017). These small population of 
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CSCs may be the driving force for the increased glycolysis of Cr(VI)-transformed 
cells. 
Energy metabolism is a balanced mechanism controlled by catabolic 
(glycolysis and oxidative phosphorylation) and anabolic (gluconeogenesis) 
reactions. Fructose-1, 6-bisphosphatase (FBP1), a rate limiting enzyme in 
gluconeogenesis, catalyzes the hydrolysis of fructose-1, 6-bisphosphate to 
fructose 6-phosphate and inorganic phosphate. It has been reported that loss of 
FBP1 is correlated with advanced stage and poor prognosis of cancer (Chen et 
al. 2011; Zhang et al. 2016a). Inhibition of FBP1 increased glucose uptake and 
lactate secretion in HK-2 human renal cells and in consistent, forced expression 
of FBP1 reduced glucose uptake, lactate secretion, and glucose-derived TCA 
cycle intermediates in renal carcinoma RCC10 cells (Li et al. 2014). In CSCs low 
level of FBP1 is beneficial due to (a) induction of glycolysis and increased 
glucose uptake, facilitating the production of glycolysis intermediates and the 
energy supply during hypoxia and (b) inhibition of ROS generation induced by 
mitochondrial complex 1, protecting cells from oxidative stress (Dong et al. 
2017). In Cr(VI)-transformed cells FBP1 level is low compared to that in passage-
matched normal cells and FBP1 is lost in CSCs (Dai et al. 2017). Ectopic 
expression of FBP1 in CSCs reduced glucose uptake, lactate production, and 
glycolysis (Dai et al. 2017), indicating that FBP1 plays an important role in 
glucose metabolism. 
HIF-1α is important in angiogenesis and in cancer development (Dong et al. 
2017; Maxwell et al. 1997; Ryan et al. 1998; Vaupel 2004). Its level is elevated in 
more than half of human cancers and their metastases (Birner et al. 2000; 
Blancher et al. 2000; Giatromanolaki et al. 2001; Huss et al. 2001; Kallio et al. 
1999; Zhong et al. 1999). The occurrence of Warburg effect indicates the 
activation of oncogenic signaling, such as hypoxia inducible factor (HIF)-1α, 
resulting in promotion of glucose uptake and anabolic metabolism (Fan et al. 
2013). This transcription factor upregulates many glycolytic enzymes, in which 
their gene promoters contain consensus binding motif 5’-(C/G/T)ACGTGC(G/T)-
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3’ of HIF-1α. HIF-1α protein is rapidly degraded at normoxia via pVHL-mediated 
ubiquitin-proteasome pathway, whereas hypoxia blocks degradation of HIF-1α 
protein, leading to its accumulation (Huang et al. 1996). Stabilization of HIF-1α 
modulates metabolic adaptation to low molecular oxygen levels through increase 
of cellular glycolysis (Bertout et al. 2008). HIF-1α upregulates glucose 
transporters and glycolytic enzymes (Semenza 2010). HIF1α also upregulates 
pyruvate dehydrogenase kinases (PDKs), the enzymes control entry of glucose-
derived pyruvate into tricarboxylic acid (TCA) cycle (Kim et al. 2006; Papandreou 
et al. 2006). HIF-1α was activated in Cr(VI)-repeatedly exposed cells (Kim et al. 
2016) or in Cr(VI)-transformed cells (Kaczmarek et al. 2007). HIF-1α is able to 
bind to five glycolytic enzymes including phosphofructokinase (PFK), aldolase 
(ALDA), phosphoglycerate kinase 1 (PGK1), enolase 1 (ENO1), pyruvate kinase 
(PKM), and lactate dehydrogenase (LDHA) (Dang et al. 2008). The results from 
Table 1 show that these five enzymes were upregulated in Cr(VI)-transformed 
cells. It is very likely that HIF-1α directly binds to the promoters of these glycolytic 
enzymes. FBP1 binds to HIF-1α inhibitory domain, blocking its induction of 
glycolysis (Li et al. 2014). Thus, reduced FBP1 level in Cr(VI)-transformed cells 
may induce glycolysis through decreased binding to HIF1α.  
Phosphorylation on metabolic enzymes also contributes to aerobic 
glycolysis (Bensinger and Christofk 2012). PI3K/Akt phosphorylates hexokinase 
and PFK-2 (Elstrom et al. 2004) and promotes GLUT expression and plasma 
membrane localization (Robey and Hay 2009), suggesting that activation of 
PI3K/Akt pathway promotes the Warburg effect by stimulating glucose uptake 
and further catabolism by glycolysis. It has been demonstrated that PI3K/Akt/p38 
MAPK is responsible for HIF-1α activation in Cr(VI)-transformed cells (Kim et al. 
2016), indicating involvement of PI3K/Akt/p38 in the upregulation of glycolysis of 
Cr(VI)-transformed cells.  
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1.4 Pentose phosphate pathway (PPP)  
Pentose phosphate pathway (PPP), a classic metabolic pathway, consists 
of oxidative and non-oxidative branches. The oxidative PPP converts glucose-6-
phosphate (G6P), a glycolytic intermediate, into ribulose-5-phosphate and 
generates NADPH, which is used for glutathione production, detoxification, and 
biosynthesis of lipids. The non-oxidative branch involves reversible carbon-
exchanging reactions with the final products as fructose-6-phosphate and 
glyceraldehyde-3-phosphate, which participate in glycolysis and downstream 
metabolic pathways (Riganti et al. 2012). PPP is upregulated in many types of 
tumors (Deberardinis et al. 2008; Riganti et al. 2012). The activities of glucose-6-
phosphate dehydrogenase (G6PD) and transketolase (TKT), key PPP enzymes, 
were increased in cancer cells (Hartmannsberger et al. 2011; Jonas et al. 1992). 
An early study indicated that short-term exposure of human erythrocytes to 
Cr(VI) did not exhibit effect on any of the three PPP enzymes, glucose-6-
phosphate dehydrogenase (G6PDH), 6-phosphogluconate dehydrogenase 
(PGD), or transsketolase (TKT) (Koutras et al. 1964). Our transcriptomic analysis 
show that in Cr(VI)-transformed cells expressions of several PPP enzymes 
including phosphorybosyl pyrophosphate synthase 1 & 2 (PRPS1/2), G6PD, 
ribulose 5-phosphate 3-epimerase (RPE), transaldolase (TALDO1), PGD, ribose 
5-phosphate isomerase (RPIA), aldolase A (ALDOA), and TKT were elevated 
compared to passage-matched normal cells (Table 1). 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key transcription factor 
that regulates antioxidant proteins to neutralize ROS and to restore cellular redox 
balance (Chan et al. 2001; Kobayashi and Yamamoto 2006). This transcription 
factor plays dual roles in carcinogenesis. Activation of inducible Nrf2 decreases 
malignant cell transformation carcinogenesis via decrease of oxidative stress 
(Hayes et al. 2010; Hu et al. 2010; Sporn and Liby 2012). Conversely, 
constitutively activated Nrf2 exerts oncogenic effects by protecting cancer cells 
from oxidative stress and chemotherapeutics (Kansanen et al. 2013b; Wang et 
al. 2008). Constitutive activation of Nrf2 has been identified in several types of 
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human cancer cell lines and tumors (Lau et al. 2013; Ohta et al. 2008; Sporn and 
Liby 2012; Tong et al. 2006). Cancers with high Nrf2 level are associated with 
poor prognosis (Shibata et al. 2008; Solis et al. 2010), resistance to therapeutics, 
and rapid proliferation (Singh et al. 2008; Zhang et al. 2010). In addition to its role 
in regulation of oxidative stress, Nrf2 is also involved in the anabolic metabolism 
(Mitsuishi et al. 2012; Singh et al. 2008). Nrf2 directly activates six genes 
involved in the PPP and nicotinamide adenine dinucleotide phosphate (NADPH) 
production pathway, including G6PD, PGD, TKT, TALDO1, and malicenzyme1 
(ME1), through binding of Nrf2 to antioxidant response elements (AREs) of these 
gene promoters (Mitsuishi et al. 2012). Using [U-13C6] tracer assay, it has been 
demonstrated that Nrf2 is required for purine nucleotide synthesis (Mitsuishi et al. 
2012). During metabolic reprogramming Nrf2 redirects glucose and glutamine 
into anabolic pathways, protecting cancer cells from oxidative damage (Mitsuishi 
et al. 2012). Activation of Nrf2 increases glucose uptake through the PPP, 
subsequently producing NADPH (Hawkins et al. 2016; Heiss et al. 2013; 
Mitsuishi et al. 2012). Our studies have showed that Nrf2 is constitutively 
activated in Cr(VI)-transformed cells and inhibition of Nrf2 suppresses 
tumorigenesis of Cr(VI)-transformed cells . Whether Nrf2 regulates PPP remains 
to be investigated in Cr(VI)-transformed cells, our preliminary results indicate that 
Nrf2 positively regulates G6PD, PGD, TKT, and TALDO1, resulting in 
upregulation of PPP. 
1.5 Glutaminolysis  
Along with increased aerobic glycolysis, increased glutaminolysis is 
recognized as a key feature of the metabolic profile of cancer cells (Daye and 
Wellen 2012). In addition to glycolysis, many tumors also depend on 
glutaminolysis to fuel their cellular bioenergetics and metabolism. Glutaminolysis 
catabolizes glutamine to downstream metabolites such as glutamate and α-
ketoglutarate, important intermediates to fuel TCA cycle of tumors. Similar to 
glycolysis, glutaminolysis supplies cancer cells with both ATP and crucial 
precursors for continuous biosynthesis and accelerated proliferation (Dang 2010; 
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DeBerardinis and Cheng 2010). Table 1 shows that levels of three glutaminolytic 
enzymes including glutaminase (GLS), aspartate aminotransferase 2 (GOT2), 
and glutamine fructose-6-phosphate transaminase 1 (GFPT1) were elevated in 
Cr(VI)-transformed cells, suggesting upregulation of glutaminolysis. 
Nrf2 increases glutamine consumption through enhancing glutaminolysis 
and glutathione synthesis. Nrf2 indirectly activates transcription factor 4 (ATF4), 
which regulates serine/glycine biosynthesis enzymes, supplying the substrates 
for glutathione and nucleotide production (DeNicola et al. 2015). Nrf2 promotes 
glutathione synthesis from glutamine (Mitsuishi et al. 2012). Nrf2 induces 
glutamate cysteine ligase (GCL), a key enzyme for glutathione synthesis, by 
directly activating the GCL encoding genes (Sekhar et al. 2003). Nrf2 also 
increases the supply of cysteine by direct activation of the gene encoding 
cysteine transporter SLC7A11 (Sasaki et al. 2002). Nrf2 is constitutively activated 
in Cr(VI)-transformed cells, the mechanism of Nrf2 in regulation of glutaminolysis 
in Cr(VI)-transformed cells has not yet been reported. In consideration the 
findings from Table 1, it is very possible that Nrf2 targets GLS, which metabolizes 
glutamine to glutamate, providing a key nitrogen donor and carbon supply for the 
TCA cycle of Cr(VI)-transformed cells. 
1.6 Conclusions 
Metabolic reprogramming, a major hallmark of cancer, is characterized by 
upregulations of glycolysis, glutaminolysis, lipid metabolism and pentose 
phosphate pathway. The metabolic program provides energy and metabolites to 
support rapid growth and proliferation of cancer cells. Chronic exposure of the 
cells to Cr(VI) causes malignant transformation. Similar to other cancer cells, 
these Cr(VI)-transformed cells have increased need for nutrients, energy, and 
biosynthetic activities to produce all macromolecular components during each 
passage through cell cycle. Cr(VI)-induced tumorigenesis is a chronic process. 
Among all studies related to bioenergetic phenotype induced by Cr(VI), most of 
studies focused on the short-term exposure, only a few studies investigated the 
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metabolic activities after long-term exposure to Cr(VI). For several decades, 
there has been a concentrated effort to identify the mechanisms of Cr(VI) 
carcinogenesis. However, little has been done to determine how changes of 
genes involved in glucose and glutamine metabolism contribute to Cr(VI) 
carcinogenesis. Cr(VI) exposure interferes with metabolic transduction pathways 
through different levels, including gene expression, intracellular protein levels, 
and protein function. We speculate that oxidative stress plays an important role in 
these processes. Chronic exposure of the cells to Cr(VI) causes ROS generation, 
leading to malignant cell transformation. Cr(VI)-transformed cells exhibit reduced 
capacity to generate ROS and elevated levels of antioxidant enzymes, leading to 
development of apoptosis resistance. In Cr(VI)-transformed cells, constitutive 
activation of Nrf2 enhances the PPP and NADPH generation, promoting cell 
proliferation. A representative scheme of possible mechanisms of metabolic 
reprogramming in Cr(VI) carcinogenesis is summarized in Figure 1.  
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Table 1.1 Relative level of metabolic enzymes in Cr(VI)-transformed cells 
and passage matched normal cells 
 
Gene Symbol Target pathway BEAS-2B BEAS-2B-Cr(VI) 
ADPGK Glycolysis 0.4 ± 0.5 6.7 ± 3.2 * 
ALDOA Glycolysis/PPP 6.8 ± 4.3 254.9 ± 57.0 * 
DLAT Glycolysis 14.7 ± 1.0 21.6 ± 2.6 * 
ENO1 Glycolysis 1.5 ± 0.6 71.6 ± 0.9 * 
G6PC3 Glycolysis 50.7 ± 3.4  97.3 ± 14.9 * 
GPI Glycolysis 19.1 ± 4.0  73.8 ± 8.9 * 
HK2 Glycolysis 21.2 ± 3.8 32.1 ± 2.8 * 
PDHA1 Glycolysis 48.9 ± 4.5  158.5 ± 11.7 * 
PFKM Glycolysis 29.5 ± 4.7 83.9 ± 3.6 * 
PGK1 Glycolysis 107.5 ± 36.4 221.7 ± 68.5 
PKM Glycolysis 112.5 ± 70.6 261 ± 73.9 
G6PD PPP 29.2 ± 5.3 142.3 ± 50.2 * 
PGD PPP 6.8 ± 3.1 31.4 ± 5.9 * 
PRPS1 PPP 59.4 ± 1.9 135.2 ± 8.1 * 
PRPS2 PPP 27.2 ± 0.1 53.6 ± 5.9 * 
RPE PPP 28.1 ± 1.7 39.0 ± 4.7 * 
RPIA PPP 20.1 ± 2.5 324.3 ± 85.5 * 
TALDO1 PPP 28.8 ± 6.6 55.8 ± 7.7  * 
TKT PPP 151.9 ± 32.4 324.3 ± 85.5 * 
GFPT1 Glutaminolysis 14.4 ± 1.4 26.8 ± 6.7 * 
GLS Glutaminolysis 19.3 ± 3.7 30.3 ± 10.4 * 
 
Table 1.1 Relative level of metabolic enzymes involved in glycolysis, PPP, and 
glutaminolysis. Normal BEAS-2B cells (BEAS-2B) and Cr(VI)-transformed cells (BEAS-
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2B-Cr) were subjected for extraction and purification of RNA using RNAeasy mini kit. 
Whole transcriptome sequencing analysis was performed using HiSeq 2500 Rapid Run. 
Differentially expressed genes involved in glycolysis, PPP, and glutaminolysis were 
detected using EBseq. A false detection rate analysis with 0.05 threshold was performed 
and considered as biostatistics difference (*, p < 0.05). Data represent mean ± SD (n=3). 
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Table 1.2 Relative level of enzymes involved in oxidative phosphorylation 
in Cr(VI)-transformed cells and passage-matched normal cells 
 
Gene Symbol Mitochondrial complex BEAS-2B BEAS-2B-Cr(VI) 
NDUFA13 Complex I 58.1 ± 5.1 34.9 ± 12.2 * 
NDUFA11 Complex I 10.0 ± 0.2 6.4 ± 1.0 * 
NDUFC2 Complex I 154.6 ± 8.8 81.3 ± 23.5 * 
NDUFS8 Complex I 182.5 ± 2.0 99.2 ± 26.7 * 
NDUFS7 Complex I 71.7 ± 3.1 46.4 ± 13.4 * 
NDUFS5 Complex I 544.2 ± 63.1 271.8 ± 21.4 * 
NDUFB7 Complex I 254.3 ± 16.4 153.6 ± 29.6 * 
NDUFV1 Complex I 12.5 ± 3.2 5.8 ± 1.2 * 
NDUFA6 Complex I 105.5 ± 2.8 0.5 ± 0.8 * 
NDUFA2 Complex I 152.4 ± 21.6 72.6 ± 20.1 * 
SDHA Complex II 246.5 ± 37.5 105.6 ± 20.1 * 
UQCRC1 Complex III 108.1 ± 6.8 84.5 ± 18.0 
UQCR11 Complex III 160.3 ± 15.1 101.5 ± 4.1 * 
UQCR10 Complex III 103.6 ± 9.3 61.4 ± 9.1 * 
UQCRH Complex III 42.0 ± 3.1 26.0 ± 2.1 * 
COX4I1 Complex IV 8.3 ± 1.2 3.4 ± 1.3 * 
COX6A1 Complex IV 1.4 ± 0.5 0.7 ± 0.1 * 
COX6B1 Complex IV 4.7 ± 1.1 1.8 ± 0.7 * 
ATP5H Complex V 631.8 ± 32.6 362.8 ± 11.1 * 
ATP5L Complex V 119.5 ± 9.5 87.3 ± 19.9 * 
ATP5C1 Complex V 76.2 ± 15.7 1.6 ± 0.6 * 
 
Table 1.2 Relative level of enzymes involved in mitochondrial oxidative 
phosphorylation. The method used is the same as that in Table 1. Genes involved in 
mitochondrial oxidative phosphorylation were detected using EBseq. A false detection 
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rate analysis with 0.05 threshold was performed and considered as biostatistics 
difference (*, p < 0.05). Data represent mean ± SD (n=3).  
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Figure 1.1 Representative scheme of metabolic reprogramming in Cr(VI) 
carcinogenesis. Chronic exposure of cells to Cr(VI) causes ROS generation which is 
responsible for malignant cell transformation. Once the cells are malignant transformed, 
those cells exhibit activated PI3K/Akt, reduced ROS generation, elevated antioxidant 
expressions and HIF-1α, resulting in reduction of mitochondrial oxidative 
phosphorylation and upregulations of pentose phosphate pathway, glycolysis and 
glutaminolysis, leading to tumorigenesis. 
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CHAPTER 2. CONSTITUTIVE ACTIVATION OF NAD-DEPENDENT SIRTUIN 3 PLAYS AN 
IMPORTANT ROLE IN TUMORIGENESIS OF CHROMIUM(VI)-TRANSFORMED CELLS 
2.1 Abstract 
Chronic exposure of human bronchial epithelial BEAS-2B cells to 
hexavalent chromium (Cr(VI)) causes malignant cell transformation. NAD-
dependent Sirtuin-3 (SIRT3) regulates mitochondrial adaptive response to stress, 
such as metabolic reprogramming and antioxidant defense mechanisms. In 
Cr(VI)-transformed cells, SIRT3 was upregulated and mitochondrial ATP 
production and proton leak were reduced. Inhibition of SIRT3 by its shRNA 
further decreased mitochondrial ATP production, proton leak and mitochondrial 
mass and induced mitochondrial membrane depolarization, indicating that SIRT3 
positively regulates mitochondrial oxidative phosphorylation and maintenance of 
mitochondrial integrity. Mitophagy is critical to maintain proper cellular functions. 
In Cr(VI)-transformed cells expressions of Pink 1 and Parkin, two mitophagy 
proteins, were elevated, mitophagy remained similar as that in passage-matched 
normal BEAS-2B cells, indicating that Cr(VI)-transformed cells are mitophagy 
deficient. Knockdown of SIRT3 induced mitophagy, suggesting that SIRT3 plays 
an important role in mitophagy deficiency of Cr(VI)-transformed cells. In Cr(VI)-
transformed cells, nuclear factor-(erythroid-derived 2)-like 2 (Nrf2) was 
constitutively activated, and protein levels of p62 and p-p62Ser349 were elevated. 
Inhibition of SIRT3 or treatment with carbonyl cyanide m-chloro phenyl hydrazine 
(cccp) decreased the binding of p-p62Ser349 to Keap1, resulting in increased 
binding of Keap1 to Nrf2 and consequently reduced Nrf2 activation. The results 
from CHIP assay showed that in Cr(VI)-transformed cells binding of Nrf2 to 
antioxidant response element (ARE) of SIRT3 gene promoter was dramatically 
increased. Inhibition of SIRT3 suppressed cell proliferation and tumorigenesis of 
Cr(VI)-transformed cells. Forced expression of SIRT3 in normal BEAS-2B cells 
exhibited mitophagy deficient phenotype and increases in cell proliferation and 
tumorigenesis. The present study demonstrated that upregulation of SIRT3 
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causes mitophagy deficiency, playing an important role in cell survival and 
tumorigenesis of Cr(VI)-transformed cells. 
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2.2 Introduction  
Hexavalent chromium (Cr(VI)) has been classified as Group 1 human 
carcinogen by the International Agency for Research in Cancer (IARC). 
Environmental exposure to Cr(VI) has increased in the past decades due to 
usage of this metal in industry, agriculture, and technology endeavors (He et al. 
2005; Shallari et al. 1998; Tchounwou et al. 2012). Our previous study showed 
that chronic exposure of bronchial epithelial (BEAS-2B) cells to Cr(VI) caused 
malignant cell transformation (Kim et al. 2015a). These transformed cells 
exhibited reduced capacity of generating ROS, development of apoptosis 
resistance, and increased angiogenesis, leading to cell survival and 
tumorigenesis (Kim et al. 2015a; Kim et al. 2016; Pratheeshkumar et al. 2016; 
Wang et al. 2011). 
Mitochondria regulate energy homeostasis and cell death. Mitophagy, a 
selective form of autophagy for elimination of damaged mitochondria, is essential 
for the reduction of insufficient supply of ATP and excessive production of ROS. 
Defective mitophagy contributes to various diseases, including cancer 
(Bernardini et al. 2017; Chourasia et al. 2015; Kulikov et al. 2017). Mitophagy is 
regulated by two key mediators, the E3 ubiquitin ligase (Parkin, encoded by 
Park2 gene) and the Pten-induced putative kinase 1 (Pink1) (Durcan and Fon 
2015; Eiyama and Okamoto 2015; Wei et al. 2015). Depolarization of 
mitochondrial membrane potential (MMP) causes translocation of Pink1 to the 
outer membrane, where it phosphorylates Parkin. Phosphorylated Parkin then 
ubiquitinates outer mitochondrial membrane proteins, targeting the organelle to 
undergo lysosomal autophagical degradation (Wei et al. 2015).  
SIRT3, a major mitochondrial deacetylation enzyme, regulates metabolic 
homeostasis via mitochondria protein deacetylation (Finley and Haigis 2012; 
Giralt and Villarroya 2012). It was reported that SIRT3-deficient mice are below 
basal metabolic condition concomitant with increased mitochondrial hyper-
acetylation (Lombard et al. 2007). SIRT3 was found to be associated with 
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antioxidant response (Bell and Guarente 2011; Park et al. 2011), regulation of 
oxidative metabolism, glycolytic pathway (Finley and Haigis 2012), and 
suppression of mitophagy (Liang et al. 2013; Pi et al. 2015).  
In cancer cells energy production relies on glycolysis, instead of 
mitochondria oxidative phosphorylation. It has been reported that mitochondrial 
function is essential for the production of key biosynthetic intermediates instead 
of ATP, directly contributing to cancer cell survival and tumorigenesis (Finley and 
Haigis 2012). This study investigated the role of SIRT3 in suppressing 
mitophagy, contributing to cell survival and tumorigenesis of Cr(VI)-transformed 
cells. 
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2.3 Material and Methods  
2.3.1 Chemicals and reagents 
Sodium dichromate dehydrate (Na2Cr2O7) and carbonyl cyanide m-chloro 
phenyl hydrazine (cccp) were obtained from Sigma (St Louis, MO). Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and pen-strep-
glutamine solution were obtained from Gibco (Grand Island, NY). shRNAs and 
overexpressing vectors of SIRT3 and Nrf2 and primers for Real Time PCR were 
obtained from Origene (Rockville, MD). mKeima-Red-Mito-7 plasmid and PCD 
FL0X luciferase reporter were from Addgene. RNAeasy mini kit and plasmid prep 
kit were obtained from Qiagen (Valencia, CA). M-MLV reverse transcriptase and 
luciferase assay reagents were obtained from Promega (Madison, WI). 
AccuPrime TaqDNA polymerase high fidelity, antibodies against Alexa Fluor 488 
goat anti-mouse IgG1 and Alexa Fluor 649 goat anti-rabbit IgG1, Lipofectamine 
2000, and 10-N-Acridine Orange (NAO) were from Invitrogen (Carlsbad, CA). iQ 
SyBr green supermix was obtained from Bio-Rad (Hercules, CA). Antibodies 
against SIRT3, p62, p-p62Ser349, Parkin, Pink1, and cytochrome c were obtained 
from Cell Signaling (Danvers, MA). Antibodies against Nrf2, GAPDH, and Keap-1 
were obtained from Santa Cruz Biotechnology (Dallas, TX). Mitochondrial 
isolation kit and Pierce agarose chip kit were obtained from Thermo Scientific 
(Waltham, MA). JC-1 mitochondrial membrane potential assay kit was obtained 
from Cayman Chemical Company (Ann Arbor, MI). Matrigel was obtained from 
BD Biosciences (San Jose, CA). Chemiluminescence reagent was obtained from 
Amershan Biosciences ( Little Chalfont, United Kingdom).  
2.3.2 Cell culture and generation of Cr(VI)-transformed cells 
Human bronchial epithelial cells (BEAS-2B) were purchased from the 
American Type Culture Collection (Rockville, MD). Malignantly transformed cells 
induced by chronic exposure to Cr(VI) were generated as previously described 
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(Kim et al. 2015a). Passage-matched BEAS-2B and Cr(VI)-transformed cells 
were maintained in DMEM supplemented with 10% FBS and 1% pen-strep-
glutamine solution at 37 ˚C and 5% CO2.  
2.3.3 Detection of mitochondria ATP production and proton leak 
Cells were seeded in 96-well plates for overnight. Mitochondrial ATP 
production and proton leak were detected using Seahorse FX mitochondria 
stress test. 
2.3.4 Immunoblotting assay 
 Cells were harvested, and pellets were lysed in RIPA buffer. Protein 
concentration was measured using Bradford assay. 30 µg of protein was 
separated by SDS-PAGE and incubated with primary and secondary antibodies. 
Chemiluminescence reagent was used to detect protein levels.  
2.3.5 Plasmid transfection and establishment of stable knockdown or 
expressing cells 
Transfection was performed using Lipofectamine 2000 as described by 
the manufacturer’s protocol. Briefly, 1.5 x 106 cells were seeded and grown 
overnight.  The cells were transfected with 4 µg of plasmid and selected using 
DMEM medium containing 2 µg/ml of puromycin for two months. Expression 
levels of those proteins were detected using immunoblotting analysis. 
2.3.6  Real Time PCR 
 RNeasy mini kit was used to extract and to purify RNA from cultured cells. 
0.5 µg of purified RNA was reversed transcribed using qScript cDNA synthesis 
kit. Following primers were used: SIRT3, 5’-ACCCAGTGGCATTCCAGAC-3’ and 
5’-GGCTTGGGGTTGTGAAAGAA-3’; NQO1, 5’-TGGAAGTCGTCCCAAGAGA-3’ 
and 5’-TGTCTCCCCAGGACTCTCTCAG-3’; and GAPDH, 5’-
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GAGTCAACGGATTTGGTCGT-3’ and 5’-GACAAGCTTCCCGTTCTCAG-3’. 
qPCR was performed using Sybr Green mixture in CFX96 Real-time PCR 
Detection System (Bio-Rad) and data was analyzed using CFX manager 
software (Bio-Rad).  
2.3.7 Mitochondrial isolation 
 Passage-matched normal BEAS-2B cells and Cr(VI)-transformed cells 
were grown in cell culture medium. Mitochondrial and cytosolic isolation was 
performed using the mitochondrial isolation kit following the manufacturers 
protocol. Mitochondria lysis was performed using 2% CHAPS in tris-buffered 
saline. 30 µg of protein from cytosolic and mitochondrial fraction were used for 
immunoblotting analysis. 
2.3.8 Detection of mitochondria membrane potential 
 Mitochondria membrane potential was detected using JC-1 mitochondrial 
membrane potential assay kit as described by the manufacturer’s protocol. 
Briefly, 104 cells were seeded overnight in CO2 in incubator. The cells were 
treated with 5 µM of cccp for 4 h. J-aggregates fluorescent intensity was 
measured using Gemini XPS fluorescence microplate spectrophotometer 
(Molecular Devices).  
2.3.9 Mitochondria mass analysis 
 Mitochondria mass was measured by staining the cells with 5 µM of 10-N-
Acridine Orange (NAO) for 10 min. NAO is a fluorescent probe that stains 
mitochondria independently of its energetic state (Ferlini and Scambia 2007; Lee 
et al. 2000; Maftah et al. 1989). Cells were seeded for overnight and treated with 
5 µM of cccp for 4 h followed by incubation with 5 µM of NAO for 10 min. NAO 
fluorescence intensity was measured using Gemini XPS fluorescence microplate 
spectrophotometer (Molecular Devices).  
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2.3.10 Mito-keima mitophagy assay 
 Mito-keima-Red-Mito-7 plasmid was transfected to the cells as described 
in previous section. Cells were seeded overnight. Lysosomal mKeima 
fluorescence intensity was measured using dual-excitation radiometric pH 
measurements at 488 nm (pH 7) and 561 nm (pH 4) lasers with emission filters 
set for 620 nm and 614 nm, respectively (Lazarou et al. 2015), using Gemini XPS 
fluorescence microplate spectrophotometer (Molecular Devices).  
2.3.11 Immunoprecipitation analysis  
 Cell lysates were incubated with pre-cleaned beads and centrifuged. 
Supernatants were collected and incubated with 5 µg of primary antibody for 
overnight. After incubation with pre-cleaned beads, the samples were washed 
with PBS and centrifuged followed by adding Laemmli sample buffer. The 
samples were centrifuged, and supernatant was collected for immunoblotting 
analysis.  
2.3.12 Fluorescence immunocytochemistry analysis 
 Cells were seeded on the chamber slides for overnight, washed with PBS, 
and fixed with 4% formaldehyde followed by incubation with 1% Triton-X100. The 
cells were then incubated with 10% horse serum. Primary antibodies were added 
and incubated for overnight followed by incubation with secondary antibodies. 
The slides were mounted with Vectashield mounting medium and visualized 
using Olympus BX53 fluorescence microscope (Center Valley, PA). Relative 
colocalization was measured using CellSens Dimension software (Olympus 
corporation).  
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2.3.13 Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was performed using PierceTM agarose chip kit. DNA and 
protein were cross-linked using 1% formaldehyde. The cells were lysed and 
nuclei was digested with micrococcal nuclease. Chromatin was diluted and 
immunoprecipitated with 2 µg of Nrf2 antibody or IgG antibody. DNA-protein 
complexes were eluted from the protein A/G-agarose beads. Binding of Nrf2 to 
ARE of SIRT3 promoter was analyzed by Real Time PCR. Amplified DNA were 
separated on 2% agarose gel with Gel Red® followed by band visualization under 
ultraviolet transillumination. 
2.3.14 Luciferase assay 
 Cells were transfected with 4 μg of SIRT3 luciferase reporter for 48 h. 
Luciferase activities were measured using Glomax luminometer (Promega). Data 
were normalized to total cell count. 
2.3.15 Tumorigenesis assay 
 Female athymic nude mice (6-8 weeks old) were purchased from The 
Jackson Laboratories (Bar Harbor, ME) and housed in sterilized filter-topped 
cages in a pathogen free animal facility at the Chandler Medical Center, 
University of Kentucky. Animals were handled according to the Institutional 
Animal Care and Use Committee (IACUC) guidelines. Cells in 100 µL mixture of 
DMEM and Matrigel (BD Biosciences) were subcutaneously (s.c.) injected on the 
flank of each mouse. After 3 weeks, mice were euthanized using CO2 and the 
tumors were isolated. Tumor weight was measured, and volume was calculated 
using the formula: (length x width2)/2.  
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2.4 Results 
2.4.1 SIRT3 positively regulates mitochondrial oxidative phosphorylation 
pathway in Cr(VI)-transformed cells  
In Cr(VI)-transformed cells both protein and mRNA levels of SIRT3 were 
elevated (Figures 2.1A and 2.1B). Our recent study using RNA sequencing 
transcriptome analysis demonstrated that all five mitochondrial oxidative 
phosphorylation complexes were reduced in Cr(VI)-transformed cells compared 
to passage-matched normal BEAS-2B cells (Clementino et al. 2018). These 
results are consistent with the results from mitochondrial stress test confirming 
that mitochondrial ATP production and proton leak were reduced in Cr(VI)-
transformed cells (Figures 2.1C and 2.1D). These results suggest that 
mitochondrial ATP production is inhibited and mitochondrial oxidative 
phosphorylation pathway is defective in Cr(VI)-transformed cells. To investigate 
whether SIRT3 is involved in reduced mitochondrial ATP production in Cr(VI)-
transformed cells, SIRT3 was inhibited using its shRNA (Figure 2.1E). The 
results showed that depletion of SIRT3 decreased both mitochondrial ATP 
production and proton leak in Cr(VI)-transformed cells (Figures 2.1F and 2.1G), 
indicating that SIRT3 positively regulates mitochondrial oxidative phosphorylation 
pathway in Cr(VI)-transformed cells.  
2.4.2 SIRT3 is a negative regulator of mitophagy in Cr(VI)-transformed cells         
Mitochondria mass was reduced in Cr(VI)-transformed cells compared to 
that in passage-matched normal BEAS-2B cells (Figure 2.2A). There was no 
observable difference in mitochondria membrane potential (MMP) between 
passage-matched normal BEAS-2B cells and Cr(VI)-transformed cells (Figure 
2.2B), leading to hypothesize that in Cr(VI)-transformed cells mitophagy is 
suppressed and that upregulation of SIRT3 is responsible for the mitophagy 
suppression. Our results showed that SIRT3 knockdown decreased 
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mitochondrial membrane potential (MMP) (Figure 2.2E) and further reduced 
mitochondrial mass (Figure 2.2D). Carbonyl cyanide m-chloro phenyl hydrazine 
(cccp), a mitochondrial depolarizing agent known to induce mitophagy (Ni et al. 
2015; Wei et al. 2015), was used as a positive control. These results suggest that 
in Cr(VI)-transformed cells, upregulation of SIRT3 prevents mitochondria 
membrane potential from reduction. 
 In Cr(VI)-transformed cells, both Pink1 and Parkin were upregulated 
(Figure 2.2E). SIRT3 was localized in the mitochondria and Parkin was in the 
cytosol (Figure 2.2G), which ascertains that mitophagy was suppressed in Cr(VI)-
transformed cells. Additionally, we observed that SIRT3 knockdown reduced 
protein levels of Parkin and Pink1 (Figure 2.2G) and translocated Parkin to the 
mitochondria (Figure 2.2H). The results from Mito-keima analysis showed no 
difference in mitophagy between Cr(VI)-transformed cells and their passage-
matched normal BEAS-2B, whereas knockdown of SIRT3 induced mitophagy in 
Cr(VI)-transformed cells (Figure 2.2I). Not surprising, treatment with cccp 
induced mitophagy in both normal BEAS-2B and Cr(VI)-transformed cells. Next, 
mitophagy was measured under starvation condition. The results showed that 
under starvation mitophagy was induced in passage-matched normal BEAS-2B 
cells, but not in Cr(VI)-transformed cells (Figure 2.2J). These results indicate that 
SIRT3 suppresses mitophagy in Cr(VI)-transformed cells via stabilization of 
mitochondrial membrane potential. 
2.4.3 Upregulation of SIRT3 elevates p62 and Nrf2, leading to increased cell 
proliferation and tumorigenesis of Cr(VI)-transformed cells 
Nrf2, p62 and p-p62ser349 levels were all increased in Cr(VI)-transformed 
cells (Figure 2.3A). SIRT3 knockdown decreased levels of Nrf2, p62, and p-
p62ser349 (Figure 2.3B) and caused translocation of p62 from cytosol to 
mitochondria (Figure 2.3C). The results from Figure 2.2I showed that SIRT3 
knockdown increased mitophagy in Cr(VI)-transformed cells. These results 
suggest that upregulation of SIRT3 prevents p62 from mitophagic degradation 
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through stabilization of mitochondrial membrane potential. Keap1 binds and 
ubiquitinates Nrf2, targeting to proteasomal degradation of Nrf2 (Suzuki et al. 
2016). Keap1 has higher affinity to bind to p-p62ser349 than Nrf2 (Ichimura et al. ; 
Katsuragi et al. 2016a). SIRT3 knockdown or treatment with cccp caused a 
reduced binding between Keap1 and p-p62ser349 and an increased binding 
between Keap1 and Nrf2, resulting in decreased level of Nrf2 in Cr(VI)-
transformed cells (Figure 2.3D), demonstrating that SIRT3 regulates Nrf2 through 
increased binding of p62 to Keap-1. 
 We investigated whether upregulation of SIRT3 is essential for increased 
cell proliferation and tumorigenesis of Cr(VI)-transformed cells. The results 
showed that inhibition of SIRT3 reduced cell proliferation of Cr(VI)-transformed 
cells (Figure 2.3E). The results from in vivo xenograft tumor growth assay 
showed that in Cr(VI)-transformed cells 4 out 4 animals (100%) grew tumors and 
in SIRT3 knockdown cells 1 out of 4 animals (25%) grew tumor (Figure 2.3F). 
Moreover, tumors isolated from Cr(VI)-transformed cells were heavier (Figure 
2.3G) and bigger (Figure 2.3H) than those isolated from SIRT3 knockdown cells. 
The results from immunoblotting analysis showed the protein levels of Nrf2, p62, 
and SIRT3 were all markedly reduced in the tumor tissues from SIRT3 
knockdown cells compared to those from Cr(VI)-transformed cells (Figure 2.3I). 
These results demonstrated that SIRT3 plays an important role in the cell 
proliferation and tumorigenesis of Cr(VI)-transformed cells. 
2.4.4 Nrf2 regulates SIRT3 through direct binding to the ARE of SIRT3 gene 
promoter 
Nrf2 knockdown decreased levels of SIRT3, p62 and Parkin in Cr(VI)-
transformed cells (Figure 2.4A). SIRT3 overexpression prevented these 
reductions by Nrf2 knockdown, indicating that Nrf2 is an upstream regulator of 
SIRT3. Inhibition of Nrf2 also reduced MMP (Figure 2.4B) and mitochondrial 
mass (Figure 2.4C). SIRT3 overexpression was able to partially restore MMP 
and mitochondrial mass reduced by Nrf2 inhibition (Figures 2.4B and 2.4C). 
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Stably expressing Nrf2 in normal BEAS-2B cells was established and the results 
showed that SIRT3 level was elevated in these Nrf2-expressing BEAS-2B cells 
(Figure 2.4D), suggesting that regulation of Nrf2 on SIRT3 is not specific for 
Cr(VI)-transformed cells. Next, we explored the mechanism of regulation of Nrf2 
on SIRT3. Both SIRT3 mRNA level and promoter activities were elevated in Nrf2-
expressing normal BEAS-2B cells and Cr(VI)-transformed cells compared to 
those in normal BEAS-2B cells (Figures 2.4E and 2.4F). Nrf2 overexpression in 
normal BEAS-2B cells increased SIRT3 in both cytosol and nucleus and 
knockdown of Nrf2 by its shRNA in Cr(VI)-transformed cells reduced SIRT3 in 
nucleus (Figure 2.4G), suggesting that regulation of Nrf2 on SIRT3 maybe 
through transcription level. We analyzed human promoter sequence of SIRT3 
gene using the transcriptional regulatory element database and identified the 
antioxidant response element (ARE) of SIRT3 gene promoter (Figure 2.4H). 
Next, we conducted DNA ChIP assay. The results showed that in normal BEAS-
2B cells with Nrf2 overexpression, the binding of Nrf2 to ARE of SIRT3 promoter 
was markedly increased (Figures 2.4I and 2.4K). In Cr(VI)-transformed cells, 
knockdown of Nrf2 by its shRNA dramatically reduced the binding of Nrf2 to ARE 
of SIRT3 gene promoter (Figures 2.4J and 2.4K), demonstrating that Nrf2 
regulates SIRT3 through direct binding to the ARE of SIRT3 promoter. 
2.4.5 Constitutive activation of SIRT3 is tumorigenic 
From the above results we postulated that constitutive activation of SIRT3 
is tumorigenic. To begin, we stably expressing SIRT3 in normal BEAS-2B cells. 
Two clones from these cells were selected and grown. Overexpression of SIRT3 
in normal BEAS-2B cells increased protein levels of Nrf2, p62, p-p62ser349, and 
Parkin (Figure 2.5A). Additionally, SIRT3 was mainly located in mitochondria and 
Parkin was in the cytosol (Figure 2.5B). As expected, overexpression of SIRT3 
suppressed mitophagy (Figure 2.5C). Similar to those in Cr(VI)-transformed cells, 
forced expression of SIRT3 in normal BEAS-2B cells reduced both mitochondrial 
ATP production and proton leak (Figures 2.5D and 2.5E). Moreover, 
overexpression of SIRT3 in normal BEAS-2B cells promoted cell growth, similar 
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as that in Cr(VI)-transformed cells (Figure 2.5F). The results from in vivo tumor 
growth showed that the animals injected with normal BEAS-2B cells with SIRT3 
overexpression grew tumors (3 out of 4 animals in one clone of SIRT3 cells and 
4 out 4 animals in another clone of SIRT3 cells) (Figures 2.5G, 2.5H, and 2.5I). 
The results from immunoblotting analysis showed that these tumor tissues have 
high levels of Nrf2, p62, p-p62ser349, and Parkin (Figure 2.5J), which are similar as 
those in Cr(VI)-transformed cells. The above observations demonstrated that 
constitutive activation of SIRT3 is tumorigenic. 
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2.5 Discussion  
Mitochondrial quality control is required for the maintenance of proper 
functioning mitochondrial network and cellular metabolism, and for the prevention 
of accumulation of ROS. Given the pivotal role of mitochondria in cellular 
homeostasis, defective mitophagy is known to contribute to various diseases. 
Our previous study has demonstrated that Cr(VI)-transformed cells undergo 
metabolic reprogramming (Clementino et al. 2018). Cancer cells shift ATP 
synthesis from oxidative phosphorylation to glycolysis to produce key 
biosynthetic intermediates in the mitochondria instead of ATP (Finley and Haigis 
2012). Therefore, mitochondrial function is essential for cancer cell proliferation 
and survival. We observed that in Cr(VI)-transformed cells both mitochondrial 
ATP production and proton leak were markedly reduced. The extent of these 
reductions may depend on the malignancy or aggressiveness of these 
transformed cells. We noted that mitochondrial function may be moderately or 
not affected in Cr(VI)-transformed cells with less malignancy or aggressiveness. 
The Cr(VI)-transformed cells used in the present study are considered as 
aggressive ones as evidenced by (1) high resistance to apoptosis; (2) rapid cell 
proliferation; (3) rapid tumor growth (reaching maximum tumor volume within 3 
weeks post injection of 106 cells in the nude mice). In addition, we used 
adenocarcinomic human alveolar basal epithelial A549 cells to detect the 
mitochondrial function. Similar results were obtained as those in Cr(VI)-
transformed cells. SIRT3 regulates metabolic homeostasis via deacetylation of 
mitochondrial proteins (Finley and Haigis 2012; Giralt and Villarroya 2012). In 
human cancer cells, mutant SIRT3 reduces mitochondrial membrane potential 
and mitochondrial ATP generation (Liu et al. 2015). SIRT3 regulates oxidative 
phosphorylation (OXPHOS) at different levels. SIRT3 regulates activities of 
complexes I and III via deacetylation of these complexes’ subunits (Ahn et al. 
2008; Cimen et al. 2010). Once complexes I and III are deacetylated by SIRT3 
they produce less ROS, therefore working more efficiently (Ahn et al. 2008; 
Cimen et al. 2010; Finley and Haigis 2012). Additionally, SIRT3 regulates 
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enzymes involved in The Citric Acid (TCA) cycle. It has been reported that SIRT3 
deacetylates succinate dehydrogenase (SDH) (Finley et al. 2011) and isocytrate 
dehydrogenase 2 (IDH2) (Someya et al. 2010). SDH participates in both the TCA 
cycle and electron transport chain, therefore it is well situated to coordinate flux 
through both pathways (Finley et al. 2011). IDH2 provides reducing equivalents 
to combat oxidative stress or to promote anabolic reactions by reducing NADP to 
NADPH (Someya et al. 2010). Deacetylation of SDH and IDH2 by SIRT3 could 
potentially stimulate mitochondria oxidative capacity and protect cells against 
oxidative stress. Thus, SIRT3 is expected to play decisive role in cell survival and 
cell response to stress.  Tumors harboring mutant SIRT3 exhibit inhibited tumor 
growth and increased sensitivity to local radiation in vivo (Liu et al. 2015). The 
present study we observed that SIRT3 is constitutively activated in Cr(VI)-
transformed cells; that this constitutively activated SIRT3 is essential in the 
maintenance of mitochondrial function; contributes to cell survival and 
tumorigenesis of Cr(VI)-transformed cells. In summary these results show that 
constitutive activation of SIRT3 is tumorigenic. 
 Mitochondrial membrane potential and mitochondria mass are two 
indicators of mitochondrial integrity. PINK1 accumulates in damaged 
mitochondria, which in turn recruits Parkin, resulting in ubiquitination of 
mitochondrial proteins (Ivankovic et al. 2016). Previous studies have shown that 
upregulation of SIRT3 stabilizes MMP and maintains mitochondrial mass 
(Pellegrini et al. 2012; Yang et al. 2016; Zhang et al. 2016b). Our results showed 
that in Cr(VI)-transformed cells SIRT3 was constitutively activated, MMP 
remained unchanged, and mitochondrial mass was reduced compared to those 
in passage-matched normal BEAS-2B cells. Knockdown of SIRT3 by its shRNA 
decreased MMP and further reduced mitochondria mass. Thus we speculated 
that constitutive activation of SIRT3 is essential to maintain MMP and 
mitochondrial function in Cr(VI)-transformed cells. Under normal condition, 
mitophagy remained similar between normal BEAS-2B cells and Cr(VI)-
transformed cells. However, starvation was able to induce mitophagy in normal 
BEAS-2B cells, but not in Cr(VI)-transformed cells, indicating that mitophagy is 
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defective in Cr(VI)-transformed cells. Mitochondria membrane depolarization is 
the first step to induce mitophagy. Once MMP is reduced, Pink1 recruits Parkin to 
the mitochondria. Under the conditions which mitochondria are undamaged, 
Pink1 is imported into the mitochondrial inner membrane, where Pink1 is 
cleaved. Aberration in mitochondrial membrane potential impairs import of Pink1 
to the mitochondrial inner membrane, leading to the stabilization of Pink1 on the 
mitochondrial outer membrane (Bernardini et al. 2017). Parkin is responsible to 
target this organelle to autophagosomal destruction (Durcan and Fon 2015; 
Eiyama and Okamoto 2015; Lazarou et al. 2015; Ni et al. 2015). We have 
observed that both Pink1 and Parkin levels were elevated in Cr(I)-transformed 
cells and Parkin was mainly located in the cytoplasm, providing the explanation 
of defective mitophagy in Cr(VI)-transformed cells. 
It has been reported that SIRT3 regulates mitophagy machinery proteins 
Parkin and Pink1 (Das et al. 2014; Liang et al. 2013; Pi et al. 2015; Qiao et al. 
2016; Yu et al. 2016). We speculated that constitutively activated SIRT3 
contributes to the defective mitophagy in Cr(VI)-transformed cells. The results 
showed that in Cr(VI)-transformed cells inhibition of SIRT3 induced mitochondria 
membrane depolarization, translocated Parkin from cytosol to the mitochondria, 
and restored mitophagy. Thus we conclude that constitutively activated SIRT3 
may contribute to mitophagy deficiency of Cr(VI)-transformed cells.  
It has been reported that recruitment of autophagic adaptor p62/SQSTM1 
to the mitochondrial clusters is essential for the clearance of mitochondria 
(Geisler et al. 2010).  p62 interacts with the autophagosome membrane to target 
the mitochondria to undergo autophagosomal destruction (Chourasia et al. 2015; 
Ding and Yin 2012; Kulikov et al. 2017; Ni et al. 2015; Wei et al. 2015). We 
observed that p62 was upregulated in Cr(VI)-transformed cells. p62 was mainly 
located in the surrounding area of mitochondria, thus blocking the degradation of 
damaged mitochondria in Cr(VI)-transformed cells. Inhibition of SIRT3 caused 
translocation of p62 to the mitochondria, promoting mitochondrial degradation 
through autophagosome and mitophagy induction. 
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Nrf2 is a key transcription factor that regulates antioxidant proteins to 
neutralize ROS and to restore cellular redox balance (Lee et al. 2012; Niture et 
al. 2010; Zhang et al. 2015a). ROS play a major role in metal-induced 
carcinogenesis (Kim et al. 2015a; Kim et al. 2016; Lee and Yu 2016; Lee et al. 
2012; Pratheeshkumar et al. 2016; Son et al. 2014; Zhang et al. 2015b). 
Inducible Nrf2 decreases carcinogenesis in the early stage via decrease of 
oxidative stress (Sporn and Liby 2012), constitutively activated Nrf2 exerts 
oncogenic effects by protecting cancer cells from oxidative stress and 
chemotherapeutics (Kansanen et al. 2013a; Wang et al. 2008). Recent studies 
have highlighted its role in mitochondrial function, including regulation of 
mitophagy via interaction with p62 and Keap1 (Dinkova-Kostova and Abramov 
2015; Holmström et al. 2017). Our results showed that Nrf2 is constitutive 
activated in Cr(VI)-transformed cells. Knockdown of Nrf2 reduced SIRT3 protein 
level, mitochondria mass, and MMP. However, overexpression of SIRT3 partially 
prevents reduction of both mitochondria mass and MMP by Nrf2 knockdown. 
These results demonstrate that SIRT3 is downstream target of Nrf2 signaling in 
regulation of mitophagy in Cr(VI)-transformed cells. Previous study showed that 
Nrf2 induced SIRT3 expression in 293T cells (Satterstrom et al. 2015). The 
present study has demonstrated that Nrf2 positively regulates SIRT3 in Cr(VI)-
transformed cells via directly binding to the ARE of SIRT3 gene promoter. Cr(VI) 
induces ROS generation, activating a cellular response to prevent the generation 
of ROS or detoxify ROS.  The activation of Nrf2 pathway is considered to be the 
most important for cell survival during oxidative stress (Niture et al. 2010). Nrf2 
activates the expression of several antioxidant enzymes by directly biding to the 
ARE of their gene promoters (Niture et al. 2010). Our results showed that in 
Cr(VI)-transformed cells activation of Nrf2 causes upregulation of SIRT3, SIRT3 
upregulation acts to promote cancer cell survival and tumorigenesis. It has been 
reported that Nrf2 regulates p62 via direct its binding to the ARE of p62 gene 
promoter (Katsuragi et al. 2016b). p62 feedbacks to Nrf2 via competitive binding 
to the Keap1 (Jain et al. 2010). In the agreement of these findings, the present 
study has demonstrated that upregulation of p-p62Ser349 in Cr(VI)-transformed 
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cells competitively binds to Keap1 with Nrf2, resulting in reduced binding of 
Keap1 to Nrf2 and subsequently elevated Nrf2. Inhibition of SIRT3 decreased p-
p62Ser349, leading to increased binding of Keap1 to Nrf2, subsequently decreased 
Nrf2. Human adenocarcinomic epithelial A549 cells were also used to examine 
the effects of SIRT3 on Nrf2/p62, Pink1/Parkin, and mitochondrial functions. The 
similar results as those in Cr(VI)-transformed cells were obtained (Suppl figure 
1). In summary, these results suggest that in Cr(VI)-transformed cells (1) Nrf2 
positively regulates SIRT3  via its direct binding to ARE of SIRT3 promoter; (2) 
p62Ser349 binds to Keap1, resulting in upregulation of Nrf2; and (3) SIRT3 
feedbacks to Nrf2 via interacting with Keap1-Nrf2/p62 pathway. 
 In Cr(VI)-transformed cells SIRT3 is upregulated. Inhibition of SIRT3 
reduced cell proliferation and tumorigenesis of Cr(VI)-transformed cells, 
suggesting that SIRT3 maybe tumorigenic. Previous studies reported that SIRT3 
had oncogenic properties (Chen et al. 2014; Giralt and Villarroya 2012; Morris et 
al. 2011; Pillai et al. 2010). Our results showed that forced SIRT3 expression in 
passage-matched normal BEAS-2B cells increased levels of Nrf2, p62, p-
p62Ser349, and Parkin. Our result also showed that forced expression of SIRT3 
expression reduced mitochondrial ATP production and proton leak and 
suppressed mitophagy, which are similar as those in Cr(VI)-transformed cells. 
Importantly, forced SIRT3 expression in passage-matched normal BEAS-2B cells 
increased cell proliferation in vitro and caused tumor growth in vivo. 
 In summary, the present study demonstrated that SIRT3 is essential to 
maintain mitochondrial basal oxidative phosphorylation of Cr(VI)-transformed 
cells. Cr(VI)-transformed cells are mitophagy defective. Inhibition of SIRT3 
induces mitophagy and decreases proliferation and tumorigenesis of Cr(VI)-
transformed cells. Constitutively activated Nrf2 upregulates SIRT3 via its direct 
binding to ARE of SIRT3 promoter. SIRT3 feedbacks to Nrf2 via interacting 
Keap1/Nrf2 axis. High level of SIRT3 in normal cells is sufficient to induce tumor 
growth in xenograft animal model, indicating that SIRT3 is tumorigenic. The 
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mechanism of SIRT3 in mitophagy and tumorigenesis of Cr(VI)-transformed cells 
is summarized in Figure 6.  
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Figure 2.1 SIRT3 is a positive regulator of mitochondrial oxidative phosphorylation 
pathway in Cr(VI)-transformed cells. (A) Whole protein lysates from Cr(VI)-
transformed cells and passage-matched normal BEAS-2B were used for immunoblotting 
analysis. (B) RNA was isolated from BEAS-2B and Cr(VI)-transformed cells and 
subjected to RT-PCR analysis. (C) and (D) BEAS-2B and Cr(VI)-transformed cells were 
seeded in 96-well plates for overnight. Mitochondrial stress test was conducted using 
Seahorse analysis. Data are expressed as mean ± SD (n=8). *, p < 0.05 compared to 
those in passage-matched BEAS-2B cells. (E) Cr(VI)-transformed cells were transfected 
with or without shSIRT3. Whole protein lysate were subjected to immunoblotting 
analysis. (F) and (G) Cr(VI)-transformed cells transfected with or without shSIRT3 were 
seeded in 96-well plates for overnight followed by mitochondria stress test using 
Seahorse analysis. Data are expressed as mean ± SD (n=8). *, p < 0.05 compared to 
Cr(VI)-transformed cells without SIRT3 knockdown.  
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Figure 2.2 SIRT3 is a negative regulator of mitophagy in Cr(VI)-transformed cells. 
(A) and (B) BEAS-2B and Cr(VI)-transformed cells were seeded in 96-well plate for 
overnight. (A) Mitochondrial mass was measured via NAO fluorescence intensity and (B) 
JC-1 fluorescence intensity was measured. Data are expressed as mean ± SD (n=8). *, 
p < 0.05 compared to that in BEAS-2B cells. (C) and (D) Cr(VI)-transformed cells 
transfected with or without shSIRT3, or treated with 5µM of cccp for 4h were seeded in 
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96-well plate for overnight. (C) Mitochondrial mass was measured via NAO fluorescence 
intensity and (D) JC-1 fluorescence intensity was measured. Data are expressed as 
mean ± SD (n=8). *, p < 0.05 compared to that in Cr(VI)-transformed cells. (E) Whole 
protein lysates from Cr(VI)-transformed cells and BEAS-2B were subjected to 
immunoblotting analysis. (F) Mitochondrial and cytosolic fraction from Cr(VI)-transformed 
cells were isolated and subjected to immunoblotting analysis. (G) Whole protein lysates 
from Cr(VI)-transformed cells transfected with or without shSIRT3, or treated with 5µM of 
cccp for 4h were subjected to immunoblotting analysis. (H) Mitochondrial and cytosolic 
fraction from Cr(VI)-transformed cells transfected with or without shSIRT3, or treated 
with 5 µM of cccp for 4h were subjected to immunoblotting analysis. (I) Cr(VI)-
transformed cells transfected with or without shSIRT3, or treated with 5 µM of cccp for 
4h were seeded in 96-well plate for overnight. mKeima fluorescence intensity in dual-
excitation was measured. Data are expressed as mean ± SD (n=8). * and #, p < 0.05 
compared to that in BEAS-2B cells without cccp treatment or Cr(VI)-transformed cells, 
respectively. (J) Cr(VI)-transformed cells transfected with or without shSIRT3 were 
seeded in 96-well plate for overnight. Cells were exposed to starvation condition for 24h. 
mKeima fluorescence intensity in dual-excitation was measured. Data are expressed as 
mean ± SD (n=8). *p < 0.05 compared to control. 
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Figure 2.3 Upregulation of SIRT3 elevates p62 and Nrf2, leading to increased cell 
proliferation and tumorigenesis of Cr(VI)-transformed cells. (A) and (B) Whole 
protein lysates from BEAS-2B and Cr(VI)-transformed cells transfected with or without 
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shSIRT3 were subjected to immunoblotting analysis. (C) Cr(VI)-transformed cells 
transfected with or without shSIRT3 were subjected to fluorescence 
immunohistochemistry analysis. Relative Co-localization was measured using CellSens 
Dimension software. Images were represented one sample in each treatment group 
(Left). Fluorescence intensities were quantitated (Right). Data are expressed as mean ± 
SD (n=3). *, p < 0.05, compared to that in Cr(VI)-transformed cells-scramble. (D) Whole 
protein lysates from Cr(VI)-transformed cells transfected with or without shSIRT3, or 
treated with 5 µM of cccp for 4h were subjected to co-immunoprecipitation analysis. (E) 
BEAS-2B and Cr(VI)-transformed cells were seeded in 6-well plates for 2, 4 and 8 days 
and total cell number was counted. Data are expressed as mean ± SD (n=3). * and #, p 
< 0.05, compared to that in BEAS-2B cells or Cr(VI)-transformed cells, respectively. (F), 
(G), and (H) 6-8 week old, female immune-deficient mice were subcutaneously injected 
with Cr(VI)-transformed cells transfected with or without shSIRT3. After 8 weeks, tumor 
volumes (Length x Width2/2) were measured (H). Tumor tissues were isolated. Tumors 
were pictured (F) and weighted (G). Protein lysates were extracted from tumor tissues 
for immunoblotting analysis (I). (G) and (H), data are expressed as mean ± SD (n=4). *, 
p < 0.05 compared to that in Cr(VI)-transformed cells.  
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Figure 2.4 Nrf2 regulates SIRT3 through direct binding to the ARE of SIRT3 gene 
promoter. (A), (B), and (C) Cr(VI)-transformed cells transfected with or without shNrf2, 
or in combination with SIRT3 expression were submitted for immunoblotting analysis (A). 
(B) JC-1 analysis was performed; (C) Mitochondria mass was measured. (B) and (C) 
Data are expressed as mean ± SD (n=8). * and #, p < 0.05, compared to those in Cr(VI)-
transformed cells and Cr(VI)-transformed cells Nrf2 knockdown, respectively. (D) Whole 
lysates from BEAS-2B with or without stable Nrf2 expression were subjected to 
immunoblotting analysis. (E) RNA was isolated from BEAS-2B with or without stable 
Nrf2 expression.  mRNA level was measured using RT-PCR analysis. Data are 
expressed as mean ± SD (n=8). *, p < 0.05, compared to that in BEAS-2B Scramble 
cells. (F) BEAS-2B with or without stable Nrf2 expression and Cr(VI)-transformed cells 
with or without Nrf2 knockdown  were transfected with SIRT3 luciferase reporter. After 
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48h of transfection, the cells were seeded in 96-well plates for overnight, followed by 
luciferase measurement. Data are expressed as mean ± SD (n=8). * and #, p < 0.05, 
compared to that in BEAS-2B Scramble cells and Cr(VI)-transformed cells scramble 
cells, respectively. (G) Nuclear and cytosolic fractions from BEAS-2B with or without 
stable Nrf2 expression and Cr(VI)-transformed cells with or without Nrf2 knockdown 
were isolated and subjected to immunoblotting analysis. (H) Consensus of ARE of 
human SIRT3 gene promoter. (I)-(K) BEAS-2B with or without stable Nrf2 expression 
and Cr(VI)-transformed cells with or without Nrf2 knockdown were submitted to 
chromatin immunoprecipitation with anti-Nrf2 antibody or control rabbit IgG. Binding of 
Nrf2 to SIRT3 promoters was analyzed by PCR using specific primers. GAPDH was 
used as a control.  (I) and (J) ChIP and quantitative (q) RT-PCR. The amounts of 
immunoprecipitated DNA were normalized to the inputs and plotted. Data are mean ± 
SD (n=3). *, p < 0.05, compared to Scramble cells. (K) Amplified DNA were separated 
on agarose gel followed by band visualization under ultraviolet transillumination. 
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Figure 2.5 Constitutive activation of SIRT3 is tumorigenic. (A) BEAS-2B cells were 
transfected with SIRT3 expression vector. Whole lysates were harvested for 
immunoblotting analysis. (B) BEAS-2B cells with or without stable expression of SIRT3 
were treated with 5 µM of cccp for 4h. Mitochondrial and cytosolic fractions were isolated 
for immunoblotting analysis. (C) BEAS-2B cells with or without stable expression of 
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SIRT3 were seeded in 96-well plate for overnight. Cells were exposed to starvation 
condition for 24h. mKeima fluorescence intensity in dual-excitation was measured. Data 
are expressed as mean ± SD (n=8). *, p < 0.05, compared to control. (D) and (E) BEAS-
2B cells with or without stable expression of SIRT3 were seeded in 96-well plates for 
overnight. Mitochondrial stress test was conducted using Seahorse analysis. Data are 
expressed as mean ± SD (n=8). *, p < 0.05, compared to those in BEAS-2B cells. (F) 
BEAS-2B cells with or without stable expression of SIRT3 were seeded in 6-well plates 
for 2, 4 and 8 days and total cell number was counted. Data are expressed as mean ± 
SD (n=3). *, p < 0.05, compared to that in BEAS-2B cells. (G), (H), and (I) 6-8 week old, 
female immune-deficient mice were subcutaneously injected with BEAS-2B cells with or 
without SIRT3 stable expression. After 8 weeks, tumor volumes were measured (I). 
Tumor tissues were isolated. Tumors were pictured (G) and weighted (H). Protein 
lysates were extracted from tumor tissues for immunoblotting analysis (J).  
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Figure 2.6 The scheme of mechanism of SIRT3 in mitophagy and tumorigenesis of 
Cr(VI)-transformed cells. Chronic exposure of the cells to Cr(VI) at low dose causes 
malignant cell transformation. The malignantly transformed cells exhibit constitutive 
activated Nrf2 and SIRT3, leading to mitophagy deficiency, contributing to cell survival 
and tumorigenesis of Cr(VI)-transformed cells. 
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CHAPTER 3. CONSTITUTIVE ACTIVATION OF NRF2 INDUCES GLYCOLYTIC SHIFT IN 
CR(VI)-TRANSFORMED CELLS                    
3.1 Abstract 
 Hexavalent chromium (Cr(VI)) chronic exposure to normal BEAS-2B cells 
induces cell transformation. Cr(VI)-transformed cells are tumorigenic. Nuclear 
factor erythroid-(derived 2)-like 2 (Nrf2) is a transcription factor that regulates 
oxidative stress response. The present study investigated how Nrf2 regulates 
metabolic reprogramming in Cr(VI)-transformed cells. The results from glycolytic 
stress test showed that glycolytic ATP production was increased in Cr(VI)-
transformed cells compared to that in passage-matched normal BEAS-2B cells. 
Nrf2 overexpression in normal BEAS-2B cells increased glycolytic ATP 
production. The results from RNAseq analysis showed that Nrf2 overexpression 
in normal BEAS-2B cells activated AMPK signaling pathway. The results from 
immunoblotting analysis confirmed that in Cr(VI)-transformed cells p-AMPKThr172 
was elevated. Nrf2 knockdown in Cr(VI)-transformed cells reduced the 
phosphorylation of AMPK. Nrf2 overexpression in normal BEAS-2B cells 
increased p-AMPKThr172. In Cr(VI)-transformed cells AMPK inhibition by its 
shRNA or treatment with dorsomorphin (5 µM) reduced PFK1 and PFKFB3 
protein levels and glycolytic ATP generation. Overall, our results suggested that 
Nrf2 regulated glycolysis via activation of AMPK pathway. Furthermore, our 
results showed that forced expression of Nrf2 in BEAS-2B cells increased cell 
proliferation and tumorigenesis. Knockdown of Nrf2 reduced cell proliferation and 
tumorigenesis of Cr(VI)-transformed cells. In conclusion, the present study 
demonstrated that constitutive activation of Nrf2 in Cr(VI)-transformed cells: (1) 
increased glycolytic ATP generation; (2) activated AMPK signaling pathway; and 
(3) increased cell proliferation and tumorigenesis.  
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3.2 Introduction 
Hexavalent chromium (Cr(VI)) is classified as a Group 1 human carcinogen 
by the International Agency for Research in Cancer (IARC). It has been reported 
that chronic exposure of Cr(VI) at low dosage induced malignant cell 
transformation of human bronchial epithelial (BEAS-2B) cells and those Cr(VI)-
transformed cells are tumorigenic (Kim et al. 2015b).  
Cancer cells accumulate distinctive capabilities in order to enable increased 
cell proliferation, tumor growth and metastatic distribution. To better understand 
the biology of cancer, ten hallmarks of cancer have been stablished (Hanahan 
and Weinberg). Previous studies demonstrated the several properties of Cr(VI)-
transformed cells, including reduced capacity of generating ROS, increased cell 
proliferation, increased angiogenesis, and resistance to cell death (Kim et al. 
2016; Kim et al. 2015b; Lee et al. 2012; Pratheeshkumar et al. 2016; Wang et al. 
2011). A recent review has highlighted the importance of metabolic 
reprogramming in Cr(VI)-transformed cells (Zhang et al. 2016a).  
Our previous study has demonstrated that expressions of genes associated 
with glycolysis, pentose-phosphate pathway (PPP), and glutaminolysis were 
elevated in Cr(VI)-transformed cells compared to these in passage-matched 
normal BEAS-2B cells. In contrast, expressions of genes associated with 
oxidative phosphorylation (OXPHOS) were downregulated in Cr(VI)-transformed 
cells (Clementino et al. 2018), suggesting that Cr(VI)-transformed cells undergo 
deregulation of their cellular energetics, in accordance with the proposed 
hallmark of cancer (Hanahan and Weinberg) and the Warburg effect (Lu et al. 
2015).   
Nuclear factor erythroid-(derived 2)-like 2 (Nrf2) is a transcription factor that 
regulates antioxidants in response to oxidative stress (Kobayashi and Yamamoto 
2006). Nrf2 plays dual roles in carcinogenesis. In normal cells inducible Nrf2 
decreases oxidative stress and malignant cell transformation (Sporn and Liby 
2012). In cancer cells constitutively activated Nrf2 protects the cells from 
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oxidative stress and chemotherapeutics, promoting cell survival (Wang et al. 
2008). Nrf2 is constitutively activated in several tumors and cancer cell lines (Lau 
et al. 2013; Ohta et al. 2008; Sporn and Liby 2012; Tong et al. 2006). High level 
of Nrf2 is associated with poor prognosis (Shibata et al. 2008; Solis et al. 2010). 
Nrf2 plays an important role in regulating anabolic metabolism and glucose 
uptake (Hawkins et al. 2016; Heiss et al. 2013; Mitsuishi et al. 2012; Singh et al. 
2008). The present study investigated the role of Nrf2 in the regulation of 
metabolic reprogramming contributing to tumorigenesis of Cr(VI)-transformed 
cells. 
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3.3 Materials and Methods 
3.3.1 Chemicals and reagents 
Sodium dichromate dehydrate (Na2Cr2O7) was obtained from Sigma (St 
Louis, MO). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum 
(FBS), and pen-strep-glutamine solution were obtained from Gibco (Grand 
Island, NY). shRNAs and overexpressing vectors Nrf2 and AMPK, and primers 
for Real Time PCR were obtained from Origene (Rockville, MD). RNAeasy mini 
kit and plasmid prep kit were obtained from Qiagen (Valencia, CA). 
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA) Antibodies against Nrf2, 
hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(PFKFB3), AMP-activated protein kinase (AMPK), p-AMPKthr172, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and superoxide dismutase 2 (SOD2)
were obtained from Cell Signaling (Danvers, MA). Antibodies against 
phosphofructokinase-1 (PFK1) was obtained from Santa Cruz Biotechnology 
(Dallas, TX). Matrigel was obtained from BD Biosciences (San Jose, CA). 
Chemiluminescence reagent was obtained from Amershan Biosciences (Little 
Chalfont, United Kingdom). 
3.3.2 Cell culture 
Human bronchial epithelial cells (BEAS-2B) purchased from the American 
Type Culture Collection (ATCC) were maintained as described previously (Kim et 
al. 2015b). Briefly, passage-match BEAS-2B and Cr(VI)-transformed cells were 
maintained in DMEM supplemented with 10% FBS and 1% pen-strep-glutamine 
solution at 37 ˚C and 5% CO2. Cr(VI)-transformed cells were generated as 
described previously (Kim et al. 2015b). 
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3.3.3 Plasmid transfection and stable cell lines 
Transfection was performed using Lipofectamine 2000 as described by 
the manufacturer’s protocol. Briefly, 1.5 million cells were seeded in 6 cm dishes 
and allowed to grow for overnight.  Cells were transfected with 2-4 µg of plasmid. 
To establish stable cells, after transfection cells were cultured in DMEM media 
containing 0.02 µg/ml of puromycin for the first week. Puromycin concentration 
was increased gradually up to 2 µg/ml with 50% concentration increment every 
week. After two months, single clones were picked up and expression of target 
proteins was examined using immunoblotting analysis 
3.3.4 RNA sequence analysis 
 RNAeasy mini kit was used to extract and purify RNA. Total RNA of 
normal BEAS-2B and Cr(VI)-transformed BEAS-2B cells were collected in 
triplicates. RNA quality was accessed using RNA Nano Chip Kit. Samples with 
higher than 8 in RNA integrity umber (RIN) were selected. Libraries were 
prepared following TruSeq® Standart total RNA protocol, followed by whole 
transcriptome sequencing of 100 bp paired-end reads using HiSeq 2500 Rapid 
Run at University of Kentucky Genomics Core Laboratory. 
3.3.5 RNA sequencing data analysis 
 Transcriptome of each sample was analyzed using esembl GRCh38 
Human Transcriptome as reference. Gene expression was calculated using 
RSEM (Li and Dewey 2011) and differentially expressed (DE) genes were 
detected using EBseq (Leng et al. 2015). A false detection rate (FDR) analysis 
with 0.05 threshold was performed. The lists of DE genes were submitted to 
ENRICHr for gene ontology enrichment analysis (Kuleshov et al. 2016).  
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3.3.6 Immunoblotting analysis 
 Cell pellets were lysed in RIPA buffer. Bradford Assay was used to 
measure protein concentration. 30 µg of protein was separated by SDS-PAGE 
followed by incubation with primary and secondary antibodies. 
Chemiluminescence reagent was used to detect protein bands.  
3.3.7 Glycolytic stress tests 
 Glycolytic stress test was performed in a Seahorse 96-well XF cell culture 
microplate in conjunction with an XF96 sensor cartridge. 80 µL of growth medium 
containing 40,000 cells were seeded for overnight. The plate was submitted for 
glycolysis analysis. 
3.3.8 In vivo Tumorigenesis assay 
 Female athymic nude mice (6-8 weeks old) were purchased from Jackson 
Laboratories (Bar Harbor, ME). Animals were handled according to guidelines 
provided by the Institutional Animal Care and Use Committee (IACUC). Animals 
were housed in sterilized filter-topped cages in a pathogen free animal facility 
and the Chandler Medical Center, University of Kentucky. 100 µL mixture of 
DMEM, Matrigel (BD Biosciences) and cells were subcutaneously (s.c) injected 
on the flank of each mouse. 3 weeks after injection, mice were euthanized using 
CO2. The tumors were isolated, and pictures were captured. Both tumor volume 
and weight were measured. Tumor volume was calculated using the following 
formula: (length x width2)/2. 
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3.4 Results  
3.4.1 Increased glycolysis in Cr(VI)-transformed cells 
 Our previous study using RNAseq analysis showed that levels of genes 
associated with glycolysis, pentose phosphate pathway (PPP), and 
glutaminolysis were increased in Cr(VI)-transformed cells, while levels of genes 
associated with oxidative phosphorylation (OXPHOS) were reduced compared to 
those in passage-matched normal BEAS-2B cells (Clementino et al. 2018). In the 
present study, we performed a glycolytic stress analysis. The results showed that 
glycolysis (Figure 3.1A), glycolytic capacity (Figure 3.1B), and glycolytic reserve 
(Figure 3.1C) were all elevated in Cr(VI)-transformed cells compared to those in 
passage-matched normal BEAS-2B cells. Glycolysis is to measure extracellular 
acidification rate (ECAR) after the addition of saturating amounts of glucose. 
Glycolytic capacity is to measure the maximum ECAR rate reached after 
effectively shutting down oxidative phosphorylation, which drives glycolysis to its 
maximum capacity. Glycolytic reserve is to measure the ability of a cell to 
respond to energy demands. These three parameters reflect the ability of a cell 
to convert glucose into pyruvate, which produces ATP. Thus, our results indicate 
that glycolytic ATP production was increased in Cr(VI)-transformed cells. 
 To study enzymes involved in the elevated glycolysis, levels of 
hexokinase2 (HK2), phospho-fructo kinase 1 (PFK1) and 6-fosfofruto-2-
quinase/frutose-2,6-bifosfatase 3 (PFKFB3), key glycolytic proteins, were 
examined. The results showed that all three proteins were upregulated in Cr(VI)-
transformed cells compared to those in passage-matched normal BEAS-2B cells 
(Figure 3.1D).   
3.4.2 Nrf2 overexpression increases glycolysis in normal BEAS-2B cells 
The results from RNAseq analysis showed that Nrf2 overexpression in 
normal BEAS-2B cells caused increases of expressions of genes associated with 
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glycolysis and reduced expression of genes associated with OXPHOS 
(Supplementary Tables 1 and 2), indicating that Nrf2 may play an important role 
in metabolic reprogramming. The results from glycolytic stress test showed that 
forced overexpression of Nrf2 in BEAS-2B cells increased glycolysis, glycolytic 
capacity and glycolytic reserve (Figures 3.2A, 3.2B and 3.2C). Nrf2 
overexpression also increased expression of glycolytic proteins including HK2, 
PFK1, and PFKFB3 (Figure 3.2D). Consistently, knockdown of Nrf2 by its shRNA 
reduced levels of HK2, PFK1 and PFKFB3 in Cr(VI)-transformed cells (Figure 
3.2D). These results indicate that Nrf2 positively regulates glycolytic ATP 
generation in Cr(VI)-transformed cells. 
Next, we investigated the mechanisms of increased glycolysis in Cr(VI)-
transformed cells. The results from RNAseq analysis showed that 
overexpression of Nrf2 in normal BEAS-2B cells increased the expressions of 
genes associated with AMPK signaling pathway (Table 3.1). The genes of 
AMPK regulatory subunit and activating AMPK were upregulated, while the 
genes inhibiting AMPK were downregulated in BEAS-2B cells with Nrf2 
overexpression. Similar results were observed in Cr(VI)-transformed cells. 
Furthermore, glycolysis and lipid metabolism genes associated with AMPK 
pathway were also upregulated in those Nrf2-expressing BEAS-2B cells and 
Cr(VI)-transformed cells.  
Phosphorylation of AMPK at threonine 172, a regulatory subunit of 
AMPK, is required for AMPK activation. Phosphorylation of AMPK  was 
increased in normal BEAS-2B cells with Nrf2 overexpression and in Cr(VI)-
transformed cells (Figure 3.2E). Knockdown of Nrf2 by its shRNA in Cr(VI)-
transformed cells reduced the AMPK phosphorylation (Figure 3.2E). These 
results suggest that Nrf2 is a positive regulator of AMPK activation in Cr(VI)-
transformed cells, supporting the hypothesis that constitutive Nrf2 activation 
increases glycolysis in Cr(VI)-transformed cells via activation of AMPK signaling 
pathway.  
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3.4.3 AMPK inhibition reduces glycolysis in BEAS-2B cells with Nrf2 
overexpression and Cr(VI)-transformed cells. 
Next, we knockdown AMPK by its shRNA in BEAS-2B cells with Nrf2 
overexpression. Knockdown of AMPK by its shRNA in Cr(VI)-transformed cells 
reduced protein levels of PFK1 and PFKFB3 (Figure 3.4A). Knockdown of 
AMPK also reduced glycolysis, glycolytic capacity and glycolytic reserve in 
Cr(VI)-transformed cells (Figures 3.4B-D). These results suggest that AMPK 
knockdown blocks activation of PFKFB3/PFK1 pathway, causing reduction of 
glycolytic ATP production. 
 Dorsomorphin is a potent and selective inhibitor of AMPK (Choi et al. 
2015; Zou et al. 2015). In Cr(VI)-transformed cells, treatment with dorsomorphin 
for 24h at concentrations of 1, 2, and 5 µM reduced protein levels of p-
AMPKThr172, PFK1, and PFKFB3 (Figure 3.5A). The results from glycolytic 
stress test showed that treatment with 5µM dorsomorphin significantly reduced 
glycolysis (Figure 3.5B), glycolytic capacity (Figure 3.5C) and glycolytic reserve 
(Figure 3.5D). These results suggest that activation of AMPK regulates the 
glycolytic shift in Cr(VI)-transformed cells. 
3.4.4 Constitutive Nrf2 activation leads to increased cell proliferation and 
tumorigenesis in Cr(VI)-transformed cells 
 We investigated whether constitutive Nrf2 activation is important for 
increased cell proliferation and tumorigenesis of Cr(VI)-transformed cells. Our 
results showed that knockdown of Nrf2 by its shRNA in Cr(VI)-transformed cells 
reduced cell proliferation on the days of 6 and 9, but not on the day 2 (Figure 
3.6A). Nrf2 overexpression in normal BEAS-2B cells increased cell proliferation 
on days 6 and 9 (Figure 3.6A). The results from in vivo xenograft tumor growth 
assay showed in that 5 of 6 animals injected with Cr(VI)-transformed cells grew 
tumors (83%), and none of 6 animals injected with Cr(VI)-transformed cells with 
Nrf2 knockdown grew tumors (0%) (Figure 3.6B). None of the animals (out of 6) 
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injected with normal BEAS-2B cells grew tumors (0%), However, 4 out of 6 
animals injected with BEAS-2B cells overexpressing Nrf2 grew tumors (67%) 
(Figure 3.6B). Both the tumor volume and weight in Cr(VI)-transformed cells are 
similar as those BEAS-2B cells with Nrf2 overexpression (Figures 3.6C and 
3.6D). The results from immunoblotting analysis showed that in these tumor 
tissues levels of Nrf2, p-AMPKThr172, AMPK, HK2, PFK1, and PFKFB3 were 
detectable (Figures 3.6E and 3.6F). These results demonstrated that constitutive 
Nrf2 activation plays an important role in increased cell proliferation and 
tumorigenesis in Cr(VI)-transformed cells.  
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3.5 Discussion 
In order to adapt to biological demands of increased proliferation, cancer 
cells change their metabolism by increasing glycolysis, PPP, and glutaminolysis 
(Hanahan and Weinberg). This metabolic shift was first described by Otto 
Warburg, known as the Warburg effect (Warburg 1956a; 1956b). Metabolic 
reprogramming is currently known as one of the hallmarks of cancer (Ward and 
Thompson 2012). Our previous (Clementino et al. 2018) and current studies 
showed that in Cr(VI)-transformed cells OXPHOS was downregulated and 
glycolysis, PPP and glutaminolysis pathways were upregulated, leading to 
reduced ATP production from OXPHOS and increased ATP from glycolysis. We 
observed that in Cr(VI)-transformed cells glycolysis was elevated. The extent of 
the increase in glycolysis may depend on the malignancy or aggressiveness of 
these transformed cells. Glycolysis might not change in Cr(VI)-transformed cells 
with  less malignancy or aggressiveness. The Cr(VI)-transformed cells used in 
the present study are considered as aggressive ones as discussed in the 
Chapter 2. Our results demonstrated that Cr(VI)-transformed cells undergo 
metabolic reprogramming. 
Nrf2 plays an important role in metabolic reprogramming by inhibiting 
lipogenesis, facilitating flux through PPP, inducing purine biosynthesis, regulating 
key metabolic proteins, and by cross-talking with several oncogenes 
(Chartoumpekis et al. 2015; Costa et al. 2014; Menegon et al. 2016; Panieri and 
Santoro 2016; Wende et al. 2016). Our results showed that in Cr(VI)-transformed 
cells, constitutive Nrf2 activation induces metabolic reprogramming, leading to 
increased cell proliferation and tumorigenesis of Cr(VI)-transformed cells. The 
present study has also demonstrated that overexpression of Nrf2 in normal 
BEAS-2B cells is tumorigenic. 
HK2, PFK1, and PFKB3 are key proteins in regulation of glycolysis. These 
proteins regulate the first rate-limiting reactions of glycolysis. HK2 catabolizes the 
phosphorylation of glucose to glucose-6-phosphate (G6P) and PFK1 catabolizes 
the phosphorylation of fructose-6-phosphate (F6P). PFK1 is considered the 
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primary control point of glycolysis and it is often upregulated in cancer cells (Li et 
al. 2015). PFK1 activity is increased by fructose-2,6-biphosphate (F2,6BP), which 
is generated by phosphorylation of F6P through PFK2. In cancer cells, increased 
glucose uptake and high hexokinase activity increase F6P generation, thus 
yielding more F2,6BP, which in turn increases PFK1 activity (Alfarouk et al. 2014; 
Li et al. 2015). In Cr(VI)-transformed cells and normal BEAS-2B cells with Nrf2 
overexpression, HK2, PFK1, and PFKB3 were all upregulated. Nrf2 knockdown 
in Cr(VI)-transformed cells reduced HK2, PFK1, and PFKB3 protein levels. The 
present study has demonstrated that glycolytic shift regulated by Nrf2 is through 
HK2, PFk1, and PFKB3 in Cr(VI)-transformed cells. 
 It has been reported that Nrf2 induced glycolytic shift in cancer is 
mediated by AMPK activation (Wang et al. 2018). Our results showed that 
constitutive Nrf2 activation induces phosphorylation of AMPK at threonine 172, 
a regulatory subunit of AMPK. This phosphorylation is required for AMPK 
activation (Stein et al. 2000). Our results also showed that forced Nrf2 expression 
in normal cells increased p-AMPKThr172 level, while Nrf2 inhibition in Cr(VI)-
transformed cells reduced it, suggesting that Nrf2 is a positive regulator of 
AMPK. The results from RNAseq analysis showed that in cells with 
constitutively activated Nrf2 (normal BEA-2B cells with Nrf2 overexpression and 
Cr(VI)-transformed cells), expressions of genes associated with AMPK subunits 
and AMPK activation were increased, however, expressions of genes 
associated with AMPK inhibition were decreased. Our results also showed that 
expression of genes associated with glucose and lipid metabolism which are 
downstream of the AMPK signaling pathway were increased, demonstrating that 
AMPK is activated in Cr(VI)-transformed cells. Rab, an oncogene, is known to 
induce glucose transporter type 4 (Glut4) translocation, which leads to increased 
glucose uptake. The increase in glucose uptake elevated hexokinases activity, 
resulting in the glycolytic shift through PFK1-PFK2 pathway (Brewer et al. 2016; 
Sano et al. 2007; Sano et al. 2008). Our results showed that expression of 
Rab10, a downstream target of AMPK signaling pathway, was increased in 
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Cr(VI)-transformed cells, indicating that the role of AMPK/Rab10 signal pathway 
in glycolytic shift of Cr(VI)-transformed cells.  
 In summary, our results demonstrated that constitutive Nrf2 activation 
activates AMPK, leading to increased glycolysis, contributing to increased cell 
proliferation and tumorigenesis of Cr(VI)-transformed cells. 
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Figure 3.1 Increased glycolysis in Cr(VI)-transformed cells. (A), (B) and (C) 
Passage-matched normal BEAS-2B and Cr(VI)-transformed cells were seeded in 96-well 
plates for overnight. Glycolytic stress test was conducted using Seahorse analysis. Data 
are expressed as mean ± SD (n=8). *, p < 0.05, compared to those in passage-matched 
BEAS-2B cells. (D) Whole protein lysates from BEAS-2B cells and Cr(VI)-transformed 
cells were used for immunoblotting analysis.  
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Figure 3.2 Nrf2 overexpression in normal BEAS-2B cells increases glycolysis. (A), 
(B) and (C) Normal BEAS-2B cells transfected with or without Nrf2 plasmid were seeded 
in 96-well plates for overnight. Glycolytic stress test was conducted using Seahorse 
analysis. Data are expressed as mean ± SD (n=8). *, p < 0.05, compared to those in 
scramble passage-matched BEAS-2B cells. (D) and (E) Whole cell lysates from normal 
BEAS-2B cells transfected with or without Nrf2 plasmid, and Cr(VI)-transformed cells 
transfected with or without shNrf2 were used for immunoblotting analysis.  
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Table 3.1 Relative level of AMPK signaling pathway in Cr(VI)-transformed cells and 
passage-matched normal cells transfected with scramble or Nrf2 vector 
 
Gene Symbol Function BEAS-2B BEAS-2B-Nrf2 BEAS-2B-Cr(VI) 
PRKAG1 AMPK Subunit 9.9 ± 0.7 15.1 ± 4.4 * 18.6 ± 1.6 * 
PRKAB2 AMPK Subunit 7.3 ± 0.9 9.0 ± 1.3 * 10.0 ± 3.6 * 
PRKAA1 AMPK Subunit 29.2 ± 1.3 27.8 ± 2.4 * 21.1 ± 2.7 * 
PRKAA2 AMPK Subunit 1.3 ± 0.1 2.3 ± 0.6 * 3.4 ± 1.0 * 
EEF2K Activates AMPK 6.3 ± 0.2 7.8 ± 0.6 * # 10 ± 0.6 * 
CAMKK1 Activates AMPK 1.3 ± 1.8 8.5 ± 1.5 * 19.3 ± 2.5 * 
ADIPOR1 Activates AMPK 1.5 ± 0.3 1.6 ± 1.2 3.1 ± 1.1 * 
ADIPOR2 Activates AMPK 52.1 ± 3.8 47.9 ± 0.7 * # 41.9 ± 2.0 * 
STK11 Inhibits AMPK 24.5 ± 2.5 19.6 ± 0.5 * # 13.8 ± 0.2 * 
PPP2R5B Inhibits AMPK 19.3 ± 1.3 13 ± 0.1 * # 1.1 ± 0.1 * 
PPP2R5D Inhibits AMPK 51.7 ± 5.0 38.4 ± 2.7 * 19.5 ± 3.8 * 
PPP2CB Inhibits AMPK 86.1 ± 8.3 78.8 ± 0.4 * # 59.3 ± 3.3 * 
PPP2R3C Inhibits AMPK 19.1 ± 1.8 15.3 ± 0.8 * 4.9 ± 1.8 * 
PPP2R3B Inhibits AMPK 8.8 ± 0.9 6.4 ± 0.6 * # 3.0 ± 1.3 * 
PPP2R5E Inhibits AMPK 7.8 ± 0.5 7.2 ± 0.6 * # 4.9 ± 0.7 * 
STRADA Inhibits AMPK 18.1 ± 0.2 14.8 ± 1.6 * 6.5 ± 1.7 * 
CPT1C Fatty acid metabolism 1.0 ± 1.1 2.0 ± 0.5 * 2.7 ± 0.2 * 
MLYCD Fatty acid metabolism 0.5 ± 0.1 0.9 ± 0.1 # 1.5 ± 0.1 * 
ACACA Fatty acid metabolism 0.2 ± 0.3 4.4 ± 1.4 * # 10.8 ± 1.5 * 
SCD Lipogenesis 14.9 ± 3.0 60.6 ± 5.6 * 143.3 ± 31.5 * 
FASN Lipogenesis 6.1 ± 2.4 14.1 ± 2.5 * # 24.7 ± 3.8 
G6PC3 Glycolysis 29.0 ± 1.2 41.8 ± 3.9 * 64.0 ± 5.3 * 
PFKM Glycolysis 29.5 ± 4.7 46.3 ± 3.9 * 86.7 ± 2.9 * 
SREBF1 Glucose/lipid metabolism 22.9 ± 1.5 26.4 ± 3.2 * 35.1 ± 10.2 * 
RAB10 Oncogene 36.9 ± 3.6 55.2 ± 5.8 * 95.5 ± 24.9 * 
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Table 3.1 Relative level of AMPK signaling pathway in Cr(VI)-transformed cells and 
passage-matched normal cells with or without Nrf2 expression. Whole 
transcriptome sequencing analysis was performed using HiSeq 2500 Rapid 
Run.Differentially expressed genes involved in AMPK signalling pathway were detected 
using EBseq. Data are expressed as mean ± SD (n=3). * and #, p < 0.05, compared to 
those in scramble passage-matched BEAS-2B and Cr(VI)-transformed cells, 
respectively. 
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Figure 3.3 AMPK inhibition reduces glycolysis in normal BEAS-2B cells with Nrf2 
expression. (A) Normal BEAS-2B cells were transfected with or without Nrf2 expression 
vector or together with AMPK shRNA for 48 h. Whole protein lysates were harvested 
for immunoblotting analysis. (B), (C) and (D) Passage-matched normal BEAS-2B cells 
were transfected with or without Nrf2 expression vector, or together with AMPK shRNA 
for 48 h. The cells were seeded in 96-well plates for overnight. Glycolytic stress test was 
conducted using Seahorse analysis. Data are expressed as mean ± SD (n=8). * and #, p < 0.05, 
compared to those in BEAS-2B cells transfected with scramble or Nrf2 vector, respectively.  
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Figure 3.4 AMPK inhibition reduces glycolysis in Cr(VI)-transformed cells. (A) 
Cr(VI)-transformed cells were transfected with or without AMPK shRNA for 48 h. Whole 
protein lysates were harvested for immunoblotting analysis. (B), (C) and (D) Cr(VI)-
transformed cells transfected with or without AMPK shRNA were seeded in 96-well 
plates for overnight. Glycolytic stress test was conducted using Seahorse analysis. Data 
are expressed as mean ± SD (n=8). *, p < 0.05, compared to those in Cr(VI)-transformed 
cells.  
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Figure 3.5 Dorsomorphin treatment reduces AMPK activation and glycolysis in 
Cr(VI)-transformed cells. (A) Cr(VI)-transformed cells were treated with 0, 1, 2, and 5 
µM of Dorsomorphin for 24 h. Whole cell lysates were harvested for immunoblotting 
analysis. (B)-(D) Cr(VI)-transformed cells were treated with 0, 1, 2, and 5 µM of 
Dorsomorphin for 24 h. The cells were seeded in 96-well plates. Glycolytic stress was 
conducted using Seahorse analysis. Data are expressed as mean ± SD (n=8). *, p < 
0.05, compared to those in Cr(VI)-transformed cells without treatment. 
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Figure 3.6 Constitutive Nrf2 activation leads to increased cell proliferation and 
tumorigenesis of Cr(VI)-transformed cells. (A) Passage-matched normal BEAS-2B 
cells with or without Nrf2  and Cr(VI)-transformed cells with or without Nrf2 shRNA were 
seeded in 6-well plates. The total cell number was counted at Day 0, 2, 6, and 9. Data 
are expressed as mean ± SD (n=8). * and #, p < 0.05 compared to that in same day 
BEAS-2B cells or Cr(VI)-transformed cells, respectively. (B), (C), and (D) 6-8 week old, 
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female immune-deficient mice were subcutaneously injected with normal BEAS-2B cells 
with or without Nrf2 expression or Cr(VI)-transformed cells with or without Nrf2 shRNA. 
After 3 weeks, the animals were euthanized using CO2. The tumors were isolated and 
weighted (C) and pictures were captured (C). Tumor volumes (Length x Width2/2) were 
measured (D). (C) and (D), data are expressed as mean ± SD (n=6). (E) and (F) Protein 
lysates were extracted from tumor tissues. Immunoblotting analysis was conducted to 
determine protein levels.  
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CHAPTER 4. CONCLUSIONS 
4.1 Hexavalent Chromium in the Environment 
Chromium compounds are naturally existed in earth’s crust. Hexavalent 
chromium (Cr(VI) is a toxic form of chromium. Cr(VI) is used in electroplating, 
wood preservatives, pigments, fungicides, and  as ingredient and catalyst in 
chemical synthesis (Hausladen et al. 2018; United States. Occupational and 
Health 2009). Chromium is used to provide protective coatings to prevent 
corrosion; thus, the steel industry is a major consumer of chromium used in the 
production of stainless steel. (United States. Occupational and Health 2009). 
Workers exposed to Cr(VI) through inhalation may develop lung cancer, as well 
as irritation and/or damage to nose and lungs. Direct contact with skin and eyes 
caused irritation and/or damage to these organs (United States. Occupational 
and Health 2009). Workers inhale airborne Cr(VI) from dusts, fumes, and mists. 
Inhalation can occur while producing chromate pigments, powders and dyes; 
working near chromate electroplating; welding on stainless steel; and applying 
and removing chromate-containing paints. Skin and eyes exposure can occur 
while handling solution, coatings and cements containing Cr(VI).  
Chromium is predominantly found in nature in two oxidation states, 
chromium (Cr(III)) and hexavalent chromium (Cr(VI)). Cr(VI) typically exists as 
chromate oxyanion, HxCrO4x-2, which is a known carcinogen when exposure 
occurs via inhalation, and potentially carcinogenic when exposure happens via 
ingestion (Costa 1997; Sun et al. 2015; Welling et al. 2015). Chromate oxyanion 
is mobile in the environment; thus, it can contaminate water beds and jeopardize 
water quality. Industrial uses of chromium will lead to acute cases of groundwater 
Cr(VI)-contamination; however, oxidation of naturally occurring chromium by 
natural processes and anthropogenic activity may affect a larger area, more 
water beds, and more people (Hausladen et al. 2018). A recent study has 
analyzed the contribution of three primary Cr(VI) sources to pollute California’s 
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ground water: Cr(VI) resulting from industrial pollution, injection of anthropogenic 
oxidants of naturally occurring Cr(III), and agricultural activities that may enhance 
oxidation of naturally occurring Cr(III) (Hausladen et al. 2018). Additionally, crops 
irrigation with untreated domestic and industrial effluents may result in 
accumulation of heavy metals in soils, leading to accumulation of Cr(VI) in the 
plant tissue (Stasinos and Zabetakis 2013).  
4.2 Hexavalent Chromium Carcinogenesis 
Metals are unique among pollutant toxicants because they are all naturally 
occurring and, in many cases, are already ubiquitous to some level within the 
human environment. Thus, regardless of how safely metals are used in industrial 
processes or consumer endpoint products, some level of human exposure is 
inevitable. Metals are neither created nor destroyed by human endeavors. 
Anthropogenic usage of metals increases the concentration of metals in the 
biosphere and alter their chemical speciation form, which thereby impact their 
toxicity potential. With a few very notable exceptions, most metals are only 
sparingly recycled once used. These factors combine altogether tend to make 
metals persistent in the human environment, often resulting in prolonged 
exposures. Cr(VI) is known to induce cancer in humans.  It is classified as a 
Group1 human carcinogen by the International Agency for Research in Cancer 
(IARC). However, the mechanism by which Cr(VI) induces cancer is unknown.  
Chronic exposure of normal bronchial epithelial (BEAS-2B) cells to low 
dose of Cr(VI)  induces malignant cell transformation (Clementino et al. 2018; Dai 
et al. 2017; Kim et al. 2015a; Kim et al. 2016; Park et al. 2015; Pratheeshkumar 
et al. 2016; Zhang et al. 2015b).  Once the cells are malignantly transformed, 
these cells exhibit reduced capacity of generating ROS, development of 
apoptosis resistance,  induced angiogenesis, increased cell proliferation and 
tumorigenesis (Kim et al. 2016; Kim et al. 2015b; Lee et al. 2012; 
Pratheeshkumar et al. 2016; Wang et al. 2011).  
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Transformed cells adapt metabolism to support tumor initiation and 
progression. Altered metabolic activities directly participate in the process of cell 
transformation or support a large requirement for nucleotides, amino acids, and 
lipids for tumor growth. In malignantly Cr(VI)-transformed cells, mitochondrial 
oxidative phosphorylation is defective, pentose phosphate pathway, glycolysis, 
and glutaminolysis are upregulated. These metabolic reprogramming supports 
rapid cell proliferation and contributes to tumorigenesis of Cr(VI)-transformed 
cells. Chapter 1 summarized the current progress in the studies of metabolic 
reprogramming and Cr(VI) carcinogenesis with emphasis on the metabolic 
enzymes and oxidative stress related major oncogenic pathways. 
The study in Chapter 2 investigated the role of NAD-dependent deacetylase 
Sirtuin-3 (SIRT3) in tumorigenesis of Cr(VI)-transformed cells. The results 
showed that In Cr(VI)-transformed cells, SIRT3 was upregulated and 
mitochondrial ATP production and proton leak were reduced. Inhibition of SIRT3 
further decreased mitochondrial ATP production, proton leak and mitochondrial 
mass and increased mitochondrial membrane depolarization, indicating that 
SIRT3 positively regulates mitochondrial oxidative phosphorylation and 
maintenance of mitochondrial integrity. Mitophagy is critical to maintain proper 
cellular functions. In Cr(VI)-transformed cells expressions of Pink 1 and Parkin, 
two mitophagy proteins, were elevated, indicating that Cr(VI)-transformed cells 
are mitophagy deficient. Knockdown of SIRT3 induced mitophagy, suggesting 
that SIRT3 plays an important role in mitophagy deficiency of Cr(VI)-transformed 
cells. Our results also showed that in Cr(VI)-transformed cells binding of Nrf2 to 
ARE of SIRT3 gene promoter was dramatically increased. Inhibition of SIRT3 
suppressed cell proliferation and tumorigenesis of Cr(VI)-transformed cells. This 
study demonstrated that upregulation of SIRT3 causes mitophagy deficiency, 
playing an important role in cell survival and tumorigenesis of Cr(VI)-transformed 
cells. 
The study in Chapter 3 investigated the role of Nrf2 in regulating metabolic 
reprogramming in Cr(VI)-transformed cells. The results showed that Nrf2 is 
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constitutive activated in Cr(VI)-transformed cells. Cr(VI)-transformed cells exhibit 
reduced mitochondrial phosphorylation and increased glycolysis. Inhibition of 
Nrf2 in Cr(VI)-transformed cells increased mitochondrial phosphorylation and 
glycolysis. AMPK is a key protein to regulate glycolysis. Our results showed that 
AMPK is activated. Inhibition of AMPK reduced glycolysis of Cr(VI)-transformed 
cells. Further study suggested that Nrf2 is a positive regulator of 
AMPK/PFK1/PFK2 pathway. In summary, this study demonstrated that 
constitutive activation of Nrf2 play an important role in metabolic reprogramming, 
leading to increased cell proliferation and tumorigenesis of Cr(VI)-transformed 
cells. 
Overall these studies demonstrated that Nrf2 is constitutively activated in 
Cr(VI)-transformed cells; that Nrf2 binds to ARE of SIRT3 promoter, causing 
upregulation of SIRT3, which in turn induced  mitophagy deficiency, indicating 
importance of SIRT3 in maintenance of mitochondria mass and further in 
increased cell proliferation and tumorigenesis of Cr(VI)-transformed cells; and 
that Nrf2 is essential for metabolic reprogramming of Cr(VI)-transformed cells. 
Cr(VI)-transformed cells exhibit decreased oxidative phosphorylation and 
increased pentose phosphate pathway (PPP), glutaminolysis, and glycolysis.  
Nrf2 activates AMPK, resulting in glycolytic shift in Cr(VI)-transformed cells. The 
role of Nrf2 in Cr(VI)-transformed cells metabolic reprogramming and 
mitochondria function is summarized in Figure 4.1. 
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Figure 4.1 The scheme of the role of Nrf2 in metabolic reprogramming and 
mitochondria function of Cr(VI)-transformed cells. Chronic exposure of 
normal BEAS-2B cells to Hexavalent Chromium (Cr(VI)) at low dose induces 
malignant cell transformation. Nrf2 is upregulated in Cr(VI)-transformed cells. 
Nrf2 induces upregulation of SIRT3. SIRT3 expression leads to mitophagy 
deficiency, maintenance of mitochondria mass, increased cell proliferation and 
tumorigenesis in Cr(VI)-transformed cells. Additionally, Nrf2 expression leads to 
decreased oxidative phosphorylation, and increased glycolysis, pentose 
phosphate pathway and glutaminolisys in Cr(VI)-transformed cells. Nrf2 leads to 
the activation of AMPK signaling pathway, which contributes to the glycolytic shift 
observed in Cr(VI)-transformed cells. Futhermore, Nrf2 constitutive activation 
contributes to  the rapid cell proliferation and tumorigenesis of Cr(VI)-transformed 
cells. 
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Supplemental Figure 1 In A549 cells SIRT3 inhibition reduces p62 and Nrf2 protein 
levels, mitochondria mass, and mitochondrial oxidative phosphorylation function. 
(A) Whole lysates from A549 cells were harvested for immunoblotting analysis. (B) and 
(C) A549 cells transfected with or without shSIRT3 were seeded in 96-well plates for 
overnight. Mitochondrial stress test was conducted using Seahorse analysis. (D) A549 
cells transfected with or without shSIRT3 were seeded in 96-well plate for overnight. 
Mitochondrial mass was measured via NAO fluorescence intensity. (E) A549 cells 
transfected with shSIRT3 were seeded in 96-well plates for overnight. JC-1 fluorescence 
intensity was measured. Data are expressed as mean ± SD (n=8). *, p < 0.05, compared 
to that in scramble cells. 
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Supplementary Table 1 Relative level of metabolic enzymes in Cr(VI)-transformed 
cells and passage-matched normal cells with Nrf2 overexpression 
 
Gene Symbol Target pathway BEAS-2B BEAS-2B Nrf2 BEAS-2B-Cr(VI) 
ADPGK Glycolysis 0.4 ± 0.5 7.4 ± 0.6 * 6.7 ± 3.2 * 
ALDOA Glycolysis/PPP 6.8 ± 4.3 496.3 ± 14.2 * # 254.9 ± 57.0 * 
DLAT Glycolysis 14.7 ± 1.0 28.6 ± 1.5 * # 21.6 ± 2.6 * 
ENO1 Glycolysis 1.5 ± 0.6 1.6 ± 1.2 # 71.6 ± 0.9 * 
G6PC3 Glycolysis 50.7 ± 3.4  98.8 ± 6.7 * 97.3 ± 14.9 * 
GPI Glycolysis 19.1 ± 4.0  121.1 ± 11.2 * # 73.8 ± 8.9 * 
HK2 Glycolysis 21.2 ± 3.8 36.1 ± 1.1 * # 32.1 ± 2.8 * 
PDHA1 Glycolysis 48.9 ± 4.5  210.2 ± 11.3 * # 158.5 ± 11.7 *  
PFKM Glycolysis 29.5 ± 4.7 86.7 ± 3.9 * # 83.9 ± 3.6 * 
PGK1 Glycolysis 107.5 ± 36.4 213.9 ± 26.6 * # 221.7 ± 68.5 
PKM Glycolysis 112.5 ± 70.6 65.3 ± 18.4 # 261 ± 73.9 
G6PD PPP 29.2 ± 5.3 222.0 ± 21.4 * 142.3 ± 50.2 * 
PGD PPP 6.8 ± 3.1 13.7 ± 0.8 * # 31.4 ± 5.9 * 
PRPS1 PPP 59.4 ± 1.9 125.3 ± 4.0 * # 135.2 ± 8.1* 
PRPS2 PPP 27.2 ± 0.1 74.6 ± 2.5 * # 53.6 ± 5.9  
RPE PPP 28.1 ± 1.7 42.6 ± 2.9 * # 39.0 ± 4.7 * 
RPIA PPP 20.1 ± 2.5 67.9 ± 0.4 * # 47.5 ± 2.7 * 
TALDO1 PPP 28.8 ± 6.6 76.3 ± 8.0 * # 55.8 ± 7.7  * 
TKT PPP 151.9 ± 32.4 550.9 ± 36.0 * # 324.3 ± 85.5 * 
GFPT1 Glutaminolysis 14.4 ± 1.4 20.5 ± 2.1 * # 26.8 ± 6.7 * 
GLS Glutaminolysis 19.3 ± 3.7 28.7 ± 2.8 * 30.3 ± 10.4 
 
Supplementary Table 1 Relative level of glycolysis, PPP and glutaminolysis 
transcripts in Cr(VI)-transformed cells and passage-matched normal cells 
transfected with scramble or Nrf2 vector. Whole transcriptome sequencing analysis 
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was performed using HiSeq 2500 Rapid Run. Differentially expressed genes involved in 
AMPK signaling pathway were detected using EBseq. Data are expressed as mean ± 
SD (n=3). * and #, p < 0.05, compared to those in scramble passage-matched BEAS-2B, 
and Cr(VI)-transformed cells, respectively. 
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Supplementary Table 2 Relative level of enzymes involved in oxidative 
phosphorylation in Cr(VI)-transformed cells and passage-matched normal cells 
with Nrf2 overexpression 
 
Gene Symbol Mitochondrial complex BEAS-2B BEAS-2B Nrf2 BEAS-2B-Cr(VI) 
NDUFA13 Complex I 58.1 ± 5.1 38.4 ± 1.1 *  34.9 ± 12.2 * 
NDUFA11 Complex I 10.0 ± 0.2 5.6 ± 1.1 * 6.4 ± 1.0 * 
NDUFC2 Complex I 154.6 ± 8.8 94.2 ± 5.5 * 87.3 ± 23.5 * 
NDUFS8 Complex I 182.5 ± 2.0 137.6 ± 8.9 * # 99.2 ± 26.7 * 
NDUFS7 Complex I 71.7 ± 3.1 75.8 ± 7.6 # 46.4 ± 13.4 * 
NDUFS5 Complex I 544.2 ± 63.1 263.8 ± 15.1 * 271.8 ± 21.4 * 
NDUFB7 Complex I 254.3 ± 16.4 161.1 ± 15.7 * 153.6 ± 29.6 * 
NDUFV1 Complex I 12.5 ± 3.2 6.3 ± 2.2 * 5.8 ± 1.2 * 
NDUFA6 Complex I 105.5 ± 2.8 0.0 ± 0.0 * 0.5 ± 0.8 * 
NDUFA2 Complex I 152.4 ± 21.6 67.9 ± 2.6 * 72.6 ± 11.0 * 
SDHA Complex II 246.5 ± 37.5 128.2 ± 7.7 * 105.6 ± 20.1 * 
UQCRC1 Complex III 108.1 ± 6.8 116.5 ± 9.7 # 84.5 ± 18.0 
UQCR11 Complex III 160.3 ± 15.1 91.7 ± 11.2 * 101.5 ± 4.1 * 
UQCR10 Complex III 103.6 ± 9.3 85.0 ± 7.1 * # 61.4 ± 9.1 * 
UQCRH Complex III 42.0 ± 3.1 23.1 ± 1.6 * 26.0 ± 2.1 * 
COX4I1 Complex IV 8.3 ± 1.2 8.1 ± 1.7 # 3.4 ± 1.3 * 
COX6A1 Complex IV 1.4 ± 0.5 1.4 ± 0.3 # 0.7 ± 0.1 * 
COX6B1 Complex IV 4.7 ± 1.1 4.2 ± 0.2 # 2.5 ± 0.5 * 
ATP5H Complex V 631.8 ± 32.6 364.9 ± 14.5 * 362.8 ± 11.1 * 
ATP5L Complex V 119.5 ± 9.5 108.5 ± 8.2 87.3 ± 19.9 * 
ATP5C1 Complex V 76.2 ± 15.7 2.6 ± 1.0 * 1.6 ± 0.6 * 
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Supplementary Table 2 Relative level of Oxidative Phosphorylation transcripts in 
Cr(VI)-transformed cells and passage-matched normal cells transfected with 
scramble or Nrf2 vector. Whole transcriptome sequencing analysis was performed 
using HiSeq 2500 Rapid Run. Differentially expressed genes involved in AMPK signaling 
pathway were detected using EBseq. Data are expressed as mean ± SD (n=3). * and #, 
p < 0.05, compared to those in scramble passage-matched BEAS-2B and Cr(VI)-
transformed cells, respectively. 
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